Colon organoids and methods of making and using same

By regulating signal transduction pathways to differentiate precursor cells in vitro to form human colon organoids, the problem of large intestine organoid generation has been solved, providing an effective model for studying colon diseases.

CN118909916APending Publication Date: 2024-11-08CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410839175.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-03-30
Filing Date
2017-12-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the current technology, the methods for generating large intestine organoids are not yet mature, which limits the research and model building for diseases such as colitis and colon cancer.

Method used

By modulating signal transduction pathways, particularly BMP signaling, precursor cells are guided to differentiate in vitro into a defined endoderm, and further differentiate into human colon organoids (HCO), thus mimicking the development of the colon.

Benefits of technology

HCOs with colonic characteristics and functions were successfully generated in vitro and can maintain regional recognition and maturation after in vivo transplantation, which can be used to study diseases such as colitis and colon cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909916A_ABST
    Figure CN118909916A_ABST
Patent Text Reader

Abstract

Disclosed herein are methods for the in vitro differentiation of precursor cells into definitive endoderm by modulating the signaling pathway, which definitive endoderm can be further differentiated into human colon organoids (HCOs). Further disclosed are HCOs and methods of using HCOs, which may be used, for example, for HCOs to determine the efficacy and / or toxicity of potential therapeutic agents against a disease selected from the group consisting of colitis, colon cancer, polyp syndrome and / or irritable bowel syndrome.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application with application number 201780073347.0 and invention name “Colon organoids and methods for their preparation and use”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 429,948, filed December 5, 2016, and International Application No. PCT / US17 / 64600, filed December 5, 2017, the entire contents of which are incorporated herein by reference for all purposes.

[0004] Government support clause

[0005] This invention was made with government support under Grants EB021780, DK103117, and AI116491 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art

[0006] While the generation of gastric and small intestinal organoids from pluripotent stem cells (PSCs) has revolutionized the study of human gastrointestinal (GI) development and disease, efforts to generate large intestinal organoids have lagged, in part due to a lack of a robust understanding of hindgut development. Summary of the invention

[0007] Disclosed herein are methods for differentiating precursor cells in vitro into definitive endoderm by modulating signaling pathways, which can be further differentiated into human colonic organoids (HCOs). Further disclosed are HCOs and methods of using HCOs, which can be used, for example, to determine the efficacy and / or toxicity of potential therapeutic agents for a disease selected from colitis, colon cancer, polyposis syndrome, and / or irritable bowel syndrome. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] The application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0009] Those skilled in the art will appreciate that the drawings described below are for illustration purposes only and are not intended to limit the scope of the present teachings in any way.

[0010] Figure 1.Bmp signaling regulates Satb2 expression in mouse and frog embryos. (A) Whole-mount pSmad158 (red) and Foxa2 (green) staining of e8.5 mouse embryos showing nuclear staining around the developing hindgut (n=6). (B) Illustration of optical sections from the boxed region in (A) showing pSmad1 / 5 / 8 staining in the hindgut mesoderm and endoderm (D, dorsal; V, ventral). (C) Schematic diagram of mouse embryos isolated at the headfold stage and cultured for 2 days with or without Bmp inhibition with DMH-1. (D, E) Whole-mount pSmad1 / 5 / 8 (red) and Foxa2 (green) staining of DMSO (0) and DMH-1 (E) treated embryos after 48 hours of culture. (F) Quantification of pSmad1 / 5 / 8 and pSmad2 / 3 staining relative to Cdx2 in embryos cultured in DMSO or DMH-1 (n=3 embryos per condition). (GJ) Whole-mount immunostaining of mouse embryos for Cdx2 (green), Satb2 (red), and Foxa2 (white) after 2 days of culture in DMSO (G, H) or DMH-1 (I, J) (n=6 for each condition). Arrows in HJ point to the approximate location of the yolk stalk (BA1, first brachial arch). (K) Quantification of Satb2 expression in mouse embryos treated with DMSO or DMH-1. (L) Schematic diagram of Bmp inhibition in tropical Xenopus embryos. In situ hybridization of Satb2 in tropical Xenopus embryos treated with DMSO (M) or DMH-1 (R). The white dashed lines in (M) and (R) depict the section planes used for subsequent analysis. mx and md = maxillary and mandibular processes of the first brachial arch. Cba = caudal brachial arch. Immunofluorescence of Satb2 (red), pSmad1 / 5 / 8 (green), DAPI (blue) and color merged images from Xenopus tropicalis embryos treated with DMSO (NQ) or DMH-1 (SV). Scale bars = 100 μm in GH and 50 μm in all other figures. **p<0.01 and ***p 0.001 for two-tailed t-test.

[0011] Figure 2.BMP2 induces SATB2 and the posterior HOX code in human intestinal spheroids. (A) Schematic diagram of the intestinal spheroid patterning protocol. (BD) BMP signaling levels measured by pSMAD1 / 5 / 8 (red) staining of spheroids treated with NOGGIN (B), no treatment (C), and BMP2 (D) for 12 hours. (E) pSmad1 / 5 / 8 staining of adult mouse colon, showing increased BMP signaling at the top of the crypts. (FH) SATB2 expression in spheroids treated with NOGGIN (F), no treatment (G), and BMP2 (H) for 72 hours. (I) Quantification of the percentage of SATB2+CDH1+ epithelium after patterning. (J) Principal component analysis of newborn spheroids and spheroids after 3 days of patterning. (K) Gene ontology analysis of differentially expressed genes between BMP vs. NOG treated spheroids. (L) Plot of TPM (transcripts per million) values ​​of spheroids before and after patterning. The samples analyzed were spheroids before patterning (n=2), and NOGGIN, control, and BMP2 treated spheroids 3 days after patterning (n=4 per group). For quantification in I, 20 organoids from at least 3 experiments were examined. Error bars represent SD. Scale bar=50 microns. ****ps 0.0001, determined by two-tailed t-test.

[0012] Figure 3. Regional patterning is maintained in human intestinal organoids after prolonged in vitro culture. (AD) Whole-mount immunofluorescence and QPCR analysis of 28-day-old organoids with the proximal marker ONECUTI (green), generated by treating spheroids with NOGGIN, control or BMP2 for the first 3 days. Staining with CDX2 (red) and DAPI (blue) was also used to detect epithelium and mesenchyme. (EH) Expression of the post-marker SATB2 (red) detected by IF and by QPCR. (IL) Analysis of the pan-goblet cell marker MUC2 (red) by IF and by QPCR. (MP) Analysis of the colon-specific goblet cell marker MUC5B (red) by IF. The number of MUC5B+ cells was quantified in (P). (QS) Analysis of pattern markers in isolated mesenchymal cultures relative to whole organoids. QPCR analysis of CDH1 (Q), proximal HOX gene HOXD3 (R) and distal HOX gene HOXA13 (S) in intact organoids and in mesenchymal cultures derived from NOGGIN, control or BMP2 treated organoids. CDH1 was observed only in intact organoids containing epithelial cells. Error bars represent SEM. For IF, a minimum of 10 organoids from at least 3 different experiments were examined for each condition. For QPCR, a minimum of 5 biological replicates from 2 independent experiments were examined. Scale bar = 100 microns. **p 5 0.01 and ****p 5 0.0001, determined by two-tailed t-test.

[0013] Figure 4. In response to the expression of the proendocrine transcription factor NEUROGENIN 3, HCO but not HIO generates colon-specific enteroendocrine cells. (AB) Schematic diagram of the doxycycline-inducible NEUROG3 lentiviral construct and doxycycline induction protocol used to generate the IPSC72.3 inducible NEUROG3 line. Whole-mount staining of 35-day-old organoids patterned with NOGGIN (C, F), untreated (D, G) or BMP (E, H) with chromogranin A (green), CDX2 (red) and INSL5 (white). (CE) Untreated organoids (-Dox) and (FH) organoids with expressed NEUROG3 (+Dox). The insets in E and H show enlarged views of INSL5 staining. (I, J) QPCR analysis of NEUROG3 induction of enteroendocrine cells in HIO and HCO as measured by CHGA (I) and for INSL5 (J) expression. Data are representative of 2 different experiments of organoids treated with NOGGIN (n=3), control (n=3), or BMP (n=6). Error bars represent SEM. Scale bar = 50 μm. *p<0.05, determined by two-tailed t-test.

[0014] Figure 5 HIOs and HCOs retain regional identity after in vivo transplantation. (AE) H&E staining of biopsies from human jejunum and colon and NOGGIN-derived HIOs, control HIOs, and BMP2-derived HCOs transplanted under the mouse kidney capsule and grown in vivo for 8-10 weeks. Samples from the same conditions were stained with the proximal intestinal marker GATA4 (FJ), the distal intestinal marker SATB2 (K-0), the Paneth cell marker DEFAS (PT), and the colon-specific goblet cell marker MUC5B (UY). Note that although the GATA4 and SATB2 double staining was performed in different channels, they were performed on the same slide in panel (F-0) and are shown as separate pseudo-colored (red) images. For human biopsies, n = 2. For transplanted NOGGIN-treated organoids, n = 12, for control organoids, n = 7, and for BMP2-treated organoids, n = 16. Scale bar = 50 pm.

[0015] Figure 6Organoids grown in vivo express regionally specific hormones. Analysis of expression of regionally expressed hormones (AD) ghrelin (GHRL), motilin (MLN), (EH) GIP, (IL) GLP-1, (MP) PYY, and (QT) INSL5 in HIOs and HCOs grown under the mouse kidney capsule for 8–10 weeks. Proximally enriched hormones GHRL, GIP, and MLN were enriched in NOGGIN and control HIOs (AH). Distally enriched hormones GLP-1 and PYY were enriched in BMP2-derived HCOs (1–0). The colon-specific hormone INSL5 was only present in HCOs (QT). Data represent a minimum of five transplanted organoids per condition. Insets in (A) and (B) show GHRL and MLN double-positive cells. (D, H, L, P, T) FPKM values ​​for GHRL, MLN, GIP, GLP1, PYY, and INSL5 were derived from RNA-seq data. FPKM values ​​represent 3 biological replicates per condition. Scale bar = 30 μm.

[0016] Figure 7 . Comprehensive transcriptional analysis of HIO and HCO and comparison with human small intestine and colon. (A) Principal component analysis comparing human adult and fetal small intestine and colon to transplanted HIO and HCO. (B) Hypergeometric means test comparing human adult small intestine to HIO and human adult colon to HCO. (C) 4-way scatter plot comparing transcripts differentially expressed in human small intestine and colon compared with HIO and HCO.

[0017] Figure 8 Gata4 and Satb2 mark discrete regional boundaries during development of the small and large intestine. (A) Whole-mount staining of Gata4 (green) and Satb2 (red) in e9.5 mouse embryos showing the expression boundary at the yolk stalk (n=9). (B) Model of the e11.5 intestine depicting Gata4 and Satb2 expression domains showing transition zones of low Gata4 and low Satb2 expression. Whole body staining of Gata4 and Satb2 in e11.5 mouse embryos, showing the posterior boundary of Gata4 and the anterior boundary of Satb2 at the yolk stalk (n=3). (FH) Whole body staining of Satb2 and Foxa2 in e12.5 mouse embryos, showing that the anterior boundary of Satb2 expression is maintained (n=3). (I) Whole body staining of Gata4 and Satb2 in proximal intestine isolated from e16.5 mouse embryos (n=6). (J) Whole body staining of Gata4 and Satb2 in distal small and large intestine isolated from e16.5 mouse embryos (n=6). Staining of GATA4 and SATB2 in sections of (K) human jejunum (n=2) and (L) colon (n=2). Scale bars = 50 μm (BD) and 100 μm (EM). The dotted lines in (C) and (F) indicate the approximate location of the umbilicus. Abbreviations: ys, yolk stalk; cb, cecal bud; tz, transition zone; mx, maxillary portion of the first brachial arch; and md, mandibular portion of the first brachial arch; ti, terminal ileum; icj, ileocecal junction.

[0018] Fig. 9 .SATB2 is expressed in GATA4-negative human small and large intestine. SATB2 staining in the human adult duodenum, small intestine, appendix, colon, and rectum showed that SATB2 expression was present in the distal small intestine and throughout the large intestine. GATA4 and SATB2 were analyzed from publicly available RNA-seq data from human adult and fetal intestinal samples. The samples mapped included human adult duodenum (HuSI_Duo_A), human adult small intestine distal to the duodenum (HuSI_Dist_A), human adult colon (HuColon_A), and human fetal small intestine (HuSI_F). (C) Analysis of GATA4 and SATB2 expression from microarray data generated by Wang et al. 2015 for fetal intestinal stem cells from the duodenum (Duo), jejunum (Jej), ileum (lle), ascending colon (AC), transverse colon (TC), and descending colon grown in an air-liquid interface (ALI). r2 values ​​were determined using the CORREL function in Excel.

[0019] Fig.10.BMP mediates SHH activation of posterior HOX genes. (A) Previous model of SHH-mediated activation of posterior HOX genes. (B) New model of SHH-mediated activation of posterior HOX genes and BMP-mediated activation of endodermal HOX genes. (C) QPCR analysis of HOX factors after treatment with NOGGIN, control, Smoothened agonist (SAG), or BMP2. (D) Model of BMP4-dependent activation of the HOX13 gene induced by SAG. (E) QPCR analysis of HOXA13 after 3 days in organoids treated with control, 5 μM SAG, 5 μM SAG+NOG, and BMP2. (F) Model of SHH-independent activation of the HOX13 gene induced by exogenous recombinant human BMP2. (G) QPCR analysis of HOXA13 after 3 days in organoids treated with control, BMP, and BMP+Cyclopamine (n=6 for each condition).

[0020] Fig.11 .Extended in vitro culture allows goblet cell maturation. (A) Quantification of the percentage of CDX2+SATB2+ cells in patterned and subsequently re-patterned organoids. QPCR analysis of HOXB13 (B) and HOXD13 (C) in 28-day-old organoids. (DF) Whole-mount and (Gl) cross-sectional staining of 44-day-old NOGGIN, control, and BMP-treated organoids with CDH1 (green), CDX2 (red), and MUC2 (white). (JL) Staining of sections from 44-day-old BMP2-treated organoids. White arrows point to goblet cells in the process of secreting mucin 2. For QPCR, a minimum of 5 biological replicates from 2 independent experiments were examined. For IF, a minimum of 10 organoids per condition were examined. Scale bar = 50 pm.

[0021] Fig.12 .BMP patterning of organoids is stable in vitro and in vivo. (A) Efficiency of organoid engraftment of NOGGIN, control, and BMP patterned organoids. Quantification of the percentage of GATA4+CDX2+ cells (B) and SATB2+CDX2+ cells (C) in transplanted patterned organoids. FPKM values ​​for GATA4 (D) SATB2 (E) DEFAS (F) and MUCSB (G) in transplanted organoids are from RNA-seq data. (HI) MUC2 (red) staining of human jejunal and colon biopsies (n=2 per region) and (JL) transplanted organoids (n=5 per condition). Scale bar = 50 μm.

[0022] Fig.13. Organoids grown in vitro and in vivo contain enteroid progenitors. Representative whole-mount (A, F, K) and section (B, G, L) images of CDH1 and GFP from organoids derived from H9-LGR5-GFP treated with NOGGIN, control, or BMP. CDX2 (red) and SOX9 (green) staining on sections from organoids treated with (CE) NOGGIN, (HJ) control, or (MO) BMP2. Representative images of CDX2 and LGR5-GFP (P, S, V), CDX2 and SOX9 (Q, T, W), and CDH1 and KI67 (R, U, X) stained in vivo in organoids derived from NOGGIN, control, or BMP treated H9-LGR5-GFP organoids. (Y-A') Micrographs show enteroids derived from NOGGIN, control, or BMP transplants, respectively. (B'-D') QPCR analysis of proximal and distal genes in control enteroids (>100 pooled enteroids from 2 grafts) and BMP2-treated colonoids (>50 colonoids from 1 graft). Scale bar = 50 μm.

[0023] Fig.14 Ribosomal and immune cell signatures are differentially expressed between transplanted organoids and primary human tissues. (A) Principal component analysis of patterned transplanted organoids and human adult and fetal small intestine and colon. (B) Gene ontology analysis of genes upregulated in transplants versus human primary tissues. (C) Gene ontology analysis of genes upregulated in human primary tissues versus transplants.

[0024] Fig.15 .(A) Whole mount immunofluorescence staining of HCOs after 15 days of growth in Matrigel. HCO cultures were stained for the endothelial marker CD31 (green) and the hindgut epithelial marker CDX2 (red). Cultures were also stained for the hematopoietic cell marker PU.1 (red right). (B) Schematic diagram of hematopoietic progenitor cell analysis. Cells were collected from HCOs, centrifuged and stained using Giemsa Wright or plated in Methocult medium to analyze hematopoietic cell differentiation. (C) Representative images of Giemsa Wright stained cells with morphology consistent with differentiation into macrophages, neutrophils, basophils, and eosinophils. (D) Representative images of colonies formed after 14 days in Methocult. Erythrocyte, macrophage, and granulocyte colonies were present in cells derived from HCOs but not in cells derived from NOGGIN treated HIOs.

[0025] Fig.16.(A) Immunofluorescence staining of human colon biopsies or HCO grown in Matrigel for 28 days. Staining was performed for CD68, a marker for macrophages. (B) CYTOF analysis of CD14 and CD16 in HIO and HCO. A small percentage of CD14+ / CD16+ cells were present in HCO (blue squares) but not in HIO. In addition, CD16 single positive cells were present in HCO, indicating that monocytes were present in the culture. (C) Luminex array analysis of supernatants collected from 14 and 28 day old HIO and HCO. IL6 and IL8 were detected in 28 day old HCO (BMP), but not in HIO. (D) Luminex array analysis of supernatants collected from 14 and 28 day old HIO and HCO. Macrophage-specific cytokines MIP1A and MIP1B were detected in 14 and 28 day old HCO (BMP), but not in 14 or 28 day old HIO. DETAILED DESCRIPTION

[0026] definition.

[0027] Unless otherwise noted, terms are to be understood according to conventional usage by those of ordinary skill in the relevant art.

[0028] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, according to the practice in the art, "about" can mean within a standard deviation of 1 or greater. Alternatively, "about" can mean a range of up to 20%, or up to 10%, or up to 5%, or up to 1% of a given value. Alternatively, particularly for biological systems or processes, the term can mean the order of magnitude of a value, preferably within 5 times, more preferably within 2 times. Where specific values ​​are described in the application and claims, unless otherwise indicated, the term "about" should be assumed to mean within an acceptable error range for the specific value.

[0029] As used herein, the term "totipotent stem cells" (also referred to as omnipotent stem cells) are stem cells that can differentiate into both embryonic and extraembryonic cell types. Such cells can build a complete, viable organism. These cells are formed by the fusion of egg and sperm cells. The cells produced by the first few divisions of the fertilized egg are also totipotent.

[0030] As used herein, the term "pluripotent stem cell (PSC)", also commonly referred to as PS cell, encompasses any cell that can differentiate into almost any cell, i.e., cells derived from any of the three germ layers (germinal epithelium), including endoderm (inner stomach wall, gastrointestinal tract, lungs), mesoderm (muscle, bone, blood, urogenital) and ectoderm (epidermal tissue and nervous system). PSCs can be descendants of totipotent cells, derived from embryonic stem cells (including embryonic germ cells) or obtained by inducing non-pluripotent cells (such as adult somatic cells) by forcing the expression of certain genes.

[0031] As used herein, the term "induced pluripotent stem cells (iPSCs)", also often abbreviated as iPS cells, refers to a type of pluripotent stem cells artificially derived from normal non-pluripotent cells (such as adult somatic cells) by inducing "forced" expression of certain genes.

[0032] As used herein, the term "embryonic stem cells (ESC)", also often abbreviated as ES cells, refers to cells that are pluripotent and derived from the inner cell mass of a blastocyst (i.e., an early embryo). For the purposes of the present invention, the term "ESC" is sometimes also broadly used to encompass embryonic germ cells.

[0033] As used herein, the term "precursor cell" encompasses any cell that can be used in the methods described herein, through which one or more precursor cells obtain the ability to self-renew or differentiate into one or more specialized cell types. In some aspects, the precursor cell is pluripotent or has the ability to become pluripotent. In some aspects, the precursor cell is subjected to the treatment of external factors (e.g., growth factors) to obtain pluripotency. In some aspects, the precursor cell can be omnipotent (or omnipotent) stem cells; pluripotent stem cells (induced or non-induced); pluripotent stem cells; oligopotent stem cells and unipotent stem cells. In some aspects, the precursor cell can be from an embryo, an infant, a child or an adult. In some aspects, the precursor cell can be a somatic cell subjected to treatment so that pluripotency is conferred by genetic manipulation or protein / peptide treatment.

[0034] In developmental biology, cell differentiation is the process by which less specialized cells become more specialized cell types. As used herein, the term "directed differentiation" describes a process by which less specialized cells become specific specialized target cell types. The specificity of the specialized target cell type can be determined by any applicable method that can be used to define or change the fate of the initial cell. Exemplary methods include, but are not limited to, genetic manipulation, chemical treatment, protein treatment, and nucleic acid treatment.

[0035] As used herein, the term "cellular component" is a single gene, protein, mRNA expressed gene, and / or any other variable cellular component or protein activity, such as the degree of protein modification (e.g., phosphorylation), which is typically measured by those skilled in the art in biological experiments (e.g., by microarray or immunohistochemistry). Significant discoveries involving complex biochemical process networks related to life systems, common human diseases, and gene discovery and structure determination are now attributable to the application of cellular component abundance data as part of the research process. Cellular component abundance data can help identify biomarkers, distinguish disease subtypes, and identify toxic mechanisms.

[0036] As described herein, methods and systems are established using a time series of growth factor manipulations to mimic embryonic intestinal development in culture. Specifically, methods and systems are established to direct the in vitro differentiation of human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC) into intestinal tissue.

[0037] The generation of gastric and small intestinal organoids from pluripotent stem cells (PSCs) has revolutionized the study of human gastrointestinal (GI) development and disease. However, efforts to generate large intestinal organoids have lagged behind, in part due to a robust molecular understanding of posterior intestinal development. Here, the applicant has found that the intestinal epithelium behind the umbilical cord expresses Satb2 throughout development and after birth. The applicant further found that BMP signaling establishes Satb2+ domains in frog and mouse embryos, and that transient activation of BMP signaling is sufficient to activate the posterior HOX code and introduce human PSC-derived intestinal cultures into colonic organoids (HCOs). HCOs grown in vitro have a signature spectrum and unique cell types consistent with colonic properties. After transplantation into mice, HCOs undergo morphogenesis and maturation to form tissues with molecular, cellular, and morphological properties of the human colon. The disclosed colonic organoids can be used in future studies of colitis and colon cancer.

[0038] In one aspect, a method of inducing human colon organoid formation is disclosed. The method may comprise the following steps: (a) contacting definitive endoderm (DE) with an FGF signaling pathway activator and a WNT signaling pathway activator (e.g., a CHIRON / GSK2 inhibitor) for a period of time sufficient for the DE to form mid-hindgut spheroids, and (b) contacting the mid-hindgut spheroids of step (a) with a BMP activator and an EGF signaling pathway activator for a period of time sufficient to form the human colon organoids, wherein the human colon organoids express SATB2.

[0039] In one aspect, the DE can be derived from a precursor cell selected from the group consisting of an embryonic stem cell, an embryonic germ cell, an induced pluripotent stem cell, a mesoderm cell, a definitive endoderm cell, a posterior endoderm cell, a hindgut cell, or a combination thereof.

[0040] In one aspect, the FGF signaling pathway activator can be selected from a small molecule or protein FGF signaling pathway activator, FGF1, FGF2, FGF3, FGF4, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23 or a combination thereof. The WNT signaling pathway activator can be selected from a small molecule or protein Wnt signaling pathway activator, preferably lithium chloride; 2-amino-4,6-disubstituted pyrimidine (hetero)aryl pyrimidine; IQ1; QS11; NSC668036; DCA β-catenin; 2-amino-4-[3,4-(methylenedioxy)-benzyl-amino]-6-(3-methoxyphenyl)pyrimidine, Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, Wnt16, a GSK3 inhibitor, preferably CHIRON, or a combination thereof. In one aspect, the BMP activator can be selected from BMP2, BMP4, BMP7, BMP9, small molecules that activate the BMP pathway, proteins that activate the BMP pathway, and can include the following: Noggin, Dorsomorphin, LDN189, DMH-1, ventromophin, and combinations thereof.

[0041] In one aspect, the period of time sufficient for the DE to form mid-hindgut spheroids can be determined by the expression of CDX2 by the mid-hindgut spheroids of step (a). Such measurements are within the capabilities of one of ordinary skill in the art using routine methods.

[0042] In one aspect, the time period sufficient for the mid-hindgut spheroids to form human colon organoids is determined by the expression of SATB2 and CDX2 by cells of the human colon organoids, wherein when SATB2 and CDX2 are expressed, the mid-hindgut spheroids have formed human colon organoids. Such measurements can be used in lieu of time measurements, as the expression of the genes listed above indicates that steps (a) and (b) have been performed for a sufficient duration.

[0043] In one aspect, HCO obtained according to the methods described herein is disclosed. The HCO of the present invention can be characterized in a variety of different ways. In one aspect, the HCO can be characterized by the presence of colonic enteroendocrine cells (EEC). In one aspect, the HCO can be characterized by the presence of crypts and substantially no villi. In one aspect, the HCO can be characterized by the presence of colon-specific goblet cells. In one aspect, the HCO can be characterized by the substantial absence of Paneth cells. In one aspect, the HCO can be characterized by the ability to secrete the colon-specific hormone INSL5. Intestinal organoids can be free of one or more of immune function, innervation, vascularity, villi, and Paneth cells.

[0044] In one aspect, a method of forming colon tissue is disclosed, wherein the HCO of the invention can be implanted under the kidney capsule of a mammal, preferably a rodent, preferably an immunocompromised rodent, preferably an immunocompromised mouse.

[0045] In one aspect, the HCOs disclosed herein can be used to determine the efficacy and / or toxicity of a potential therapeutic agent for a disease selected from colitis, colon cancer, polyposis syndrome, and / or irritable bowel syndrome. The method can comprise the step of contacting the potential therapeutic agent with an HCO as described herein for a period of time sufficient to determine the efficacy and / or toxicity of the potential therapeutic agent.

[0046] In one aspect, an enteroid colonic derived from a HCO according to any preceding claim is contemplated.

[0047] In some respects, pluripotent or pluripotent stem cells can be used. In some respects, pluripotent stem cells are derived from embryonic stem cells, which are derived from the totipotent cells of early mammalian embryos and can be unlimited, undifferentiated propagation in vitro. Embryonic stem cells are pluripotent stem cells derived from the inner cell mass (i.e., early embryo) of blastocysts. The method for deriving embryonic stem cells from embryonic cells is well known in the art. For example, three cell lines (H1, H13 and H14) have normal XY karyotype, and two cell lines (H7 and H9) have normal XX karyotype. Human embryonic stem cell H9 (H9-hESC) is used for the exemplary aspects described in the present application, but it will be appreciated by those skilled in the art that methods and systems described herein are applicable to any stem cell.

[0048] Additional stem cells that can be used according to aspects of the present invention include, but are not limited to, those provided by or described in the following: a database hosted by the National Stem Cell Bank (NSCB), Human Embryonic Stem Cell Research Center at the University of California, San Francisco (UCSF); the WISC Cell Bank at the Wi Cell Institute; the University of Wisconsin Stem Cell and Regenerative Medicine Center (UW-SCRMC); Novocell, Inc. (San Diego, California); Cellartis AB (Gothenburg, Sweden); Sweden); ES Cell International Pte Ltd (Singapore); the Technion-Israel Institute of Technology (Haifa, Israel); and stem cell banks hosted by Princeton University and the University of Pennsylvania. Exemplary embryonic stem cells that can be used according to aspects of the present invention include, but are not limited to, SA01 (SA001); SA02 (SA002); ES01 (HES-1); ES02 (HES-2); ES03 (HES-3); ES04 (HES-4); ES05 (HES-5); ES06 (HES-6); BG01 (BGN-01); BG02 (BGN-02); BG03 (BGN-03); TE03 (I3); TE04 (I4); TE06 (I6); UC01 (HSF1); UC06 (HSF6); WA01 (H1); WA07 (H7); WA09 (H9); WA13 (H13); WA14 (H14).

[0049] In some aspects, stem cells are further modified to incorporate additional properties. Exemplary modified cell lines include, but are not limited to, H1 OCT4-EGFP; H9 Cre-LoxP; H9 hNanog-pGZ; H9hOct4-pGZ; H9 inGFPhES; and H9Syn-GFP.

[0050] More details about embryonic stem cells can be found in, for example, Thomson et al., 1998, “Embryonic Stem Cell Lines Derived from Human Blastocysts,” Science 282(5391):1145-1147; Andrews et al., 2005, “Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin,” Biochem Soc Trans 33:1526–1530; Martin 1980, “Teratocarcinomas and mammalian embryogenesis.” "Embryogenesis", Science 209(4458):768-776; Evans and Kaufman, 1981, "Establishment in culture of pluripotent cells from mouse embryos", Nature 292(5819):154-156; Klimanskaya et al., 2005, "Human embryonic stem cells derived without feeder cells", Lancet 365(9471):1636-1641; the entire contents of each of which are hereby incorporated by reference into this article.

[0051] Alternatively, pluripotent stem cells can be derived from embryonic germ cells (EGC), which are cells that produce gametes of organisms that reproduce sexually. EGC is derived from primordial germ cells present in the gonadal ridges of late embryos and has many characteristics of embryonic stem cells. The primordial germ cells in the embryo develop into stem cells that produce reproductive gametes (sperm or eggs) in adults. In mice and humans, it is possible to culture embryonic germ cells in tissue culture under appropriate conditions. Both EGC and ESC are pluripotent. For the purposes of the present invention, the term "ESC" is sometimes widely used to cover EGC.

[0052] Induced Pluripotent Stem Cells (iPSCs)

[0053] In some aspects, iPSC is derived by transfecting certain stem cell related genes into non-pluripotent cells (e.g., adult fibroblasts). Transfection can be achieved by viral vectors, such as retroviruses. Transfected genes include master transcription regulators Oct-3 / 4 (Pouf51) and Sox2, but it has been proposed that other genes can improve induction efficiency. After 3-4 weeks, a small amount of transfected cells begin to become similar to pluripotent stem cells in morphology and biochemistry, and are usually separated by morphological selection, doubling time or by reporter genes and antibiotic selection. As used herein, iPSC includes but is not limited to first generation iPSC, second generation iPSC in mice and human induced pluripotent stem cells.

[0054] In some aspects, iPSC can be produced based on non-viral technology. In some aspects, adenovirus can be used to transport four necessary genes into the DNA of the skin and liver cells of mice, producing cells identical to embryonic stem cells. Since adenovirus does not combine any of its own genes with the targeted host, the risk of producing tumors is eliminated. In some aspects, reprogramming can be completed by plasmids without any viral transfection system at all, but the efficiency is very low. In other aspects, the direct delivery of protein is used to produce iPSC, thus eliminating the need for viruses or genetic modification. In certain embodiments, it is possible to produce mouse iPSC using a similar method: repeating the treatment of cells with certain proteins introduced into cells by polyarginine anchoring is sufficient to induce pluripotency. In some aspects, the expression of pluripotency inducing genes can also be increased by treating somatic cells with FGF2 under hypoxic conditions.

[0055] More details about embryonic stem cells can be found in, for example, Kaji et al., 2009, “Virus free induction of pluripotency and subsequent excision of reprogramming factors,” Nature 458:771-775; Woltjen et al., 2009, “piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells,” Nature 458:766-770; Okita et al., 2008, “Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors,” Science 322(5903):949-953; Stadtfeld et al., 2008, “Generation of Induced Pluripotent Stem Cells without Viral Integration,” Cells Generated without Viral Integration),” Science 322(5903):945-949; and Zhou et al., 2009, “Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins,” Cell Stem Cell 4(5):381-384; the entire contents of each of which are hereby incorporated by reference into this article.

[0056] In some aspects, exemplary iPS cell lines include, but are not limited to, iPS-DF19-9; iPSDF19-9; iPSDF4-3; iPSDF6-9; iPS(foreskin); iPS(IMR90); and iPS(IMR90).

[0057] Definitive endoderm

[0058] The HCO of the present disclosure can be derived from a simple cell sheet called definitive endoderm (DE). Methods for obtaining definitive endoderm from precursor cells are well known in the art, as taught by D'Armour et al. 2005 and Spence et al. The anterior DE forms the foregut and its associated organs, including the liver and pancreas, and the posterior DE forms the midgut and hindgut, which form the small and large intestines and parts of the urogenital system. Studies using mouse, chick and frog embryos have shown that the establishment of anterior-posterior patterning in the DE during the gastrula stage is a prerequisite for subsequent foregut and hindgut development. The Wnt and FGF signaling pathways are considered to be key to this process and play a role in promoting the fate of the posterior endoderm and hindgut and inhibiting the fate of the anterior endoderm and foregut. The simple cuboidal epithelium of the hindgut first develops into a pseudostratified columnar epithelium and then into villi, which contain polarized columnar epithelium and a proliferative zone at the base of the villi, which corresponds to the putative progenitor cell domain.

[0059] Applicants describe herein a robust and efficient method for directed DE in vitro differentiation into intestinal tissue, specifically human colon tissue. Directed differentiation can be achieved by selectively activating certain signaling pathways in iPSCs and / or DE cells.

[0060] Additional details on pathways of intestinal development can generally be found in, for example, Sancho et al., 2004, "Signaling Pathways in Intestinal Development and Cancer," Annual Review of Cell and Developmental Biology 20:695-723; Logan and Nusse, 2004, "The Wnt Signaling Pathway in Development and Disease," Annual Review of Cell and Developmental Biology 20:781-810; Taipale and Beachy, 2001, "The Hedgehog and Wnt signalling pathways in cancer," Nature 411:349-354; Gregorieff and Clevers, 2005, "Wnt signaling in the intestinal epithelium: from endoderm to cancer." cancer)," Genes & Dev. 19:877-890; the entire contents of each of which are hereby incorporated by reference.Further details on the function of signaling pathways involved in DE development can be found in, for example, Zorn and Wells, 2009, “Vertebrate endoderm development and organ formation,” Annu Rev Cell Dev Biol 25:221-251; Dessimoz et al., 2006, “FGF signaling is necessary for establishing gut tube domains along the anterior-posterior axis in vivo,” Mech Dev 123:42–55; McLin et al., 2007, “Repression of Wnt / {beta}-catenin signaling in the anterior endoderm is essential for liver and pancreas development.” development). Development," 134:2207-2217; Wells and Melton, 2000, Development, 127:1563-1572; de SantaBarbara et al., 2003, "Development and differentiation of the intestinal epithelium," Cell Mol Life Sci 60(7):1322-1332; the entire contents of each of which are hereby incorporated by reference into this article.

[0061] Any method for producing definitive endoderm from pluripotent cells (e.g., iPSC or ESC) is applicable to the methods described herein. In some aspects, pluripotent cells are derived from morulae. In some aspects, pluripotent stem cells are stem cells. The stem cells used in these methods may include but are not limited to embryonic stem cells. Embryonic stem cells may be derived from embryonic inner cell mass or from embryonic gonadal ridges. Embryonic stem cells or germ cells may be derived from a variety of animal species, including but not limited to various mammalian species including humans. In some aspects, human embryonic stem cells are used to produce definitive endoderm. In some aspects, human embryonic germ cells are used to produce definitive endoderm. In some aspects, iPSC is used to produce definitive endoderm.

[0062] In some aspects, one or more growth factors are used in the differentiation process from pluripotent stem cells to DE cells. One or more growth factors used in the differentiation process may include growth factors from the TGF-β superfamily. In this type of aspect, one or more growth factors may include Nodal / activin and / or BMP subgroups of TGF-β superfamily growth factors. In some aspects, one or more growth factors are selected from the group consisting of Nodal, activin A, activin B, BMP4, Wnt3a, or any combination of these growth factors. In some aspects, embryonic stem cells or germ cells and iPSCs are treated with one or more growth factors for 6 hours or more; 12 hours or more; 18 hours or more; 24 hours or more; 36 hours or more; 48 hours or more; 60 hours or more; 72 hours or more; 84 hours or more; 96 hours or more; 120 hours or more; 150 hours or more; 180 hours or more; or 240 or more. In some aspects, embryonic stem cells or germ cells and iPSCs are treated with one or more growth factors at concentrations of 10 ng / ml or higher; 20 ng / ml or higher; 50 ng / ml or higher; 75 ng / ml or higher; 100 ng / ml or higher; 120 ng / ml or higher; 150 ng / ml or higher; 200 ng / ml or higher; 500 ng / ml or higher; 1,000 ng / ml or higher; 1,200 ng / ml or higher; 1,500 ng / ml or higher; 2,000 ng / ml or higher; 5,000 ng / ml or higher; 7,000 ng / ml or higher; 10,000 ng / ml or higher; or 15,000 ng / ml or higher. In some aspects, the concentration of the growth factor is maintained at a constant level throughout the treatment process. In other aspects, the concentration of the growth factor is changed during the treatment process. In some aspects, the growth factor is suspended in a culture medium comprising fetal bovine serum (FBS) with different HyClone concentrations. It will be appreciated by those skilled in the art that the protocols described herein are applicable to any known growth factor, either alone or in combination. When two or more growth factors are used, the concentration of each growth factor can be varied independently.

[0063] In some respects, use a cell group that is rich in definitive endoderm cells. In some respects, definitive endoderm cells are separated or substantially purified. In some respects, the degree of separated or substantially purified definitive endoderm cells expressing SOX17, FOXA2 and / or CXRC4 markers is greater than expressing OCT4, AFP, TM, SPARC and / or SOX7 markers. It is also contemplated that the method for enriching definitive endoderm cells is used. In some respects, it is possible to contact a cell with a reagent that is present on the definitive endoderm cell surface but not present on other cell surfaces in a mixed cell population, and then separate the cell that is combined with the reagent, separate or substantially purify the definitive endoderm cells from a mixed cell population. In some respects, the cellular component present on the definitive endoderm cell surface is CXCR4.

[0064] Additional methods for obtaining or generating DE cells useful in the present invention include, but are not limited to, those described in: U.S. Pat. No. 7,510,876 to D'Amour et al.; U.S. Pat. No. 7,326,572 to Fisk et al.; Kubol et al., 2004, "Development of definitive endoderm from embryonic stem cells in culture," Development 131: 1651-1662; D'Amour et al., 2005, "Efficient differentiation of human embryonic stem cells to definitive endoderm," Nature Biotechnology 23: 1534-1541; and Ang et al., 1993, "The formation and maintenance of the definitive endoderm lineage in the mouse: involvement of HNF3 / forkhead proteins)," Development 119:1301-1315; the entire contents of each of which are hereby incorporated by reference.

[0065] Definitive endoderm to mid / hindgut spheroids

[0066] In some aspects, the posterior endoderm cells of DE further develop into one or more specialized cell types. The definitive endoderm (DE) induced by activin can further undergo FGF / Wnt-induced posterior endoderm patterning, posterior intestinal specialization and morphogenesis, and finally an intestinal culture system that promotes intestinal growth, morphogenesis and cell differentiation into functional intestinal cell types, including intestinal epithelial cells, goblet cells, Paneth cells and enteroendocrine cells. In some aspects, human PSC is effectively directed to differentiate into intestinal epithelium in vitro, which may include secretory cells, endocrine cells and absorptive cell types. It should be understood that molecules such as growth factors can be added to any stage of development to promote the formation of intestinal tissue of a particular type.

[0067] PSC, such as ESC and iPSC, undergoes directed differentiation in a stepwise or non-stepwise manner, first differentiating into definitive endoderm (DE), then differentiating into mid / hindgut epithelium and mesenchyme (e.g., hindgut spheroids), and then differentiating into intestinal tissue. In some aspects, definitive endoderm cells and hESC are treated with one or more growth factors.

[0068] In some aspects, soluble FGF and Wnt ligands are used to mimic early hindgut specialization in culture to convert DE formed from iPSC or ESC into hindgut epithelium by directed differentiation, which effectively generates all major intestinal cell types. In humans, directed differentiation of DE is achieved by selectively activating certain signaling pathways important for intestinal development. Those skilled in the art will appreciate that altering the expression of any Wnt signaling protein in combination with any FGF ligand can produce directed differentiation as described herein.

[0069] More details are found in, for example, Liu et al., "A small-molecule agonist of the Wnt signaling pathway," Angew Chem Int Ed Engl. 44(13):1987-1990 (2005); Miyabayashi et al., "Wnt / beta-catenin / CBP signaling maintains long-term murine embryonic stem cell pluripotency," Proc Natl Acad Sci USA 104(13):5668-5673 (2007); Zhang et al., "Small-molecule synergist of the Wnt / beta-catenin signaling pathway," Angew Chem Int Ed Engl. 44(13):1987-1990 (2005); Miyabayashi et al., "Wnt / beta-catenin / CBP signaling maintains long-term murine embryonic stem cell pluripotency," Proc Natl Acad Sci USA 104(13):5668-5673 (2007); Neiiendam et al., “An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons,” J Neurochem.Shan et al., "Identification of a specific inhibitor of the dishevelled PDZ domain," Biochemistry 44(47):15495-15503 (2005); Coghlan et al., "Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription," Chem Biol. 7(10):793-803 (2000); Coghlan et al., "Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription," Chem Biol. 7(10):793-803 (2000); gene transcription), "Chemistry & Biology 7(10):793-803; and Pai et al., "Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness," Mol Biol Cell. 15(5):2156-2163 (2004); the entire contents of each of which are hereby incorporated by reference.

[0070] In some aspects, siRNAs and / or shRNAs targeted to cellular components associated with Wnt and / or FGF signaling pathways are used to activate these pathways.

[0071] Regulators / activators of the Wnt signaling pathway include Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, and Wnt16. In some aspects, the regulation of the pathway can be activated by using small molecule modulators or protein modulators to activate the above pathways or activate proteins of the above pathways. For example, small molecule modulators of the Wnt pathway include, but are not limited to, lithium chloride; 2-amino-4,6-disubstituted pyrimidine (hetero) aryl pyrimidine; IQ1; QS11; NSC668036; DCA β-catenin; 2-amino-4-[3,4-(methylenedioxy)-benzyl-amino]-6-(3-methoxyphenyl) pyrimidine. Exemplary natural inhibitors of Wnt signaling include, but are not limited to, Dkk1, SFRP proteins, and FrzB. In some aspects, external molecules include, but are not limited to, small molecules such as WAY-316606; SB-216763; or BIO (6-bromoindirubin-3'-oxime). In some aspects, siRNA and / or shRNA targeting cellular components associated with Wnt and / or FGF signaling pathways can be used to activate these pathways. Those skilled in the art will appreciate that target cellular components include, but are not limited to, SFRP proteins; GSK3, Dkk1, and FrzB. Additional modulators include molecules or proteins that inhibit GSK3, which activates the Wnt signaling pathway. Exemplary GSK3 inhibitors include, but are not limited to, for example, Chiron / CHIR99021, which inhibits GSK3β. Those of ordinary skill in the art will recognize GSK3 inhibitors suitable for practicing the disclosed methods. GSK3 inhibitors can be administered in an amount of about 1uM to about 100uM, or about 2uM to about 50uM, or about 3uM to about 25uM. Appropriate amounts and durations will be readily appreciated by those of ordinary skill in the art.

[0072] Fibroblast growth factor (FGF) is a family of growth factors involved in angiogenesis, wound healing and embryonic development. In some aspects, it will be appreciated by those skilled in the art that any FGF can be used in combination with proteins from the Wnt signaling pathway. In some aspects, soluble FGF includes but is not limited to FGF4, FGF2 and FGF3. In some embodiments, the FGF signaling pathway is activated by contacting precursor cells with one or more molecules selected from the group consisting of: FGF1, FGF2, FGF3, FGF4, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22 and FGF23. In some embodiments, siRNA and / or shRNA targeting cellular components associated with the FGF signaling pathway can be used to activate these pathways. It will be appreciated by those skilled in the art that the methods and compositions described herein related to the Wnt and FGF signaling pathways are provided by way of example. Similar methods and compositions are applicable to other signaling pathways disclosed herein.

[0073] In some aspects, DE cultures are treated with one or more modulators of a signaling pathway described herein for 6 hours or more; 12 hours or more; 18 hours or more; 24 hours or more; 36 hours or more; 48 hours or more; 60 hours or more; 72 hours or more; 84 hours or more; 96 hours or more; 120 hours or more; 150 hours or more; 180 hours or more; 200 hours or more, 240 hours or more; 270 hours or more; 300 hours or more; 350 hours or more; 400 hours or more; 500 hours or more; 600 hours or more; 700 hours or more; 800 hours or more; 900 hours or more; 1000 hours or more; 1,200 or more hours; or 1,500 hours or more.

[0074] In some aspects, DE cultures are treated with one or more modulators of a signaling pathway described herein at concentrations of 10 ng / ml or more; 20 ng / ml or more; 50 ng / ml or more; 75 ng / ml or more; 100 ng / ml or more; 120 ng / ml or more; 150 ng / ml or more; 200 ng / ml or more; 500 ng / ml or more; 1,000 ng / ml or more; 1,200 ng / ml or more; 1,500 ng / ml or more; 2,000 ng / ml or more; 5,000 ng / ml or more; 7,000 ng / ml or more; 10,000 ng / ml or more; or 15,000 ng / ml or more. In some aspects, the concentration of the signaling molecule remains constant throughout the treatment. In other aspects, the concentration of the modulator of the signaling pathway is varied during the treatment. In some aspects, the signaling molecules according to the present invention are suspended in a culture medium comprising DMEM and fetal bovine serum serine (FBS). The FBS concentration can be 2% and higher; 5% and higher; 10% or higher; 15% or higher; 20% or higher; 30% or higher; or 50% or higher. One skilled in the art will appreciate that the protocols described herein are applicable, alone or in combination, to any known modulator of the signaling pathways described herein, including but not limited to any molecule in the Wnt and FGF signaling pathways.

[0075] In the aspect that two or more signaling molecules are used to treat DE culture, the signaling molecules can be added simultaneously or separately. When two or more molecules are used, the concentration of each molecule can be varied independently.

[0076] Expression of CDX2 can be used to reveal the tendency of hindgut formation after DE is incubated with FGF signaling activators and Wnt signaling activators (e.g., FGF4 and Wnt3a) for a period of time, such as 12 hours or more; 18 hours or more; 24 hours or more; 36 hours or more; 48 hours or more; 60 hours or more; or 90 hours or more. In some aspects, a longer incubation period is required to achieve a stable posterior endoderm phenotype, as measured by prolonged expression of CDX2. In such aspects, the incubation period can be 60 hours or more; 72 hours or more; 84 hours or more; 96 hours or more; 108 hours or more; 120 hours or more; 140 hours or more; 160 hours or more; 180 hours or more; 200 hours or more; 240 hours or more; or 300 hours or more.

[0077] Alternatively, in some aspects, the absence of cellular components, such as foregut markers Sox2, Pdx1, Cldn18, and albumin, can be used to reveal directed hindgut formation. In some aspects, intestinal transcription factors CDX2, KLF5, and SOX9 can be used to represent intestinal development. In some aspects, GATA6 protein expression can be used to represent intestinal development. In these aspects, the incubation period can be 12 hours or more; 18 hours or more; 24 hours or more; 36 hours or more; 48 hours or more; 60 hours or more; or 90 hours or more. Alternatively, the incubation period can be 60 hours or more; 72 hours or more; 84 hours or more; 96 hours or more; 108 hours or more; 120 hours or more; 140 hours or more; 160 hours or more; 180 hours or more; 200 hours or more; 240 hours or more; or 300 hours or more.

[0078] In some aspects, the abundance data of cellular components, such as protein and / or gene expression levels, are determined by immunohistochemistry using a primary antibody and / or a secondary antibody targeting a molecule in a relevant signal transduction pathway. In other aspects, the abundance data of cellular components, such as protein and / or gene expression levels, are determined by microarray analysis.

[0079] Alternatively, morphological changes can be used to indicate the progress of directed differentiation. In some aspects, the hindgut spheroids are further subjected to 3-dimensional culture conditions for further maturation. In other aspects, highly curled epithelium surrounded by mesenchymal cells can be observed after the hindgut spheroids are formed. In addition, intestinal organoids; polarized columnar epithelium; goblet cells; or smooth muscle cells are observed within the following time: 6 days or more; 7 days or more; 9 days or more; 10 days or more; 12 days or more; 15 days or more; 20 days or more; 25 days or more; 28 days or more; 32 days or more; 36 days or more; 40 days or more; 45 days or more; 50 days or more; or 60 days or more.

[0080] Mid / hindgut spheroids to colonic organoids

[0081] It has been determined that, in addition to FGF and WNT signaling, bone morphogenetic proteins (BMPs), specifically BMP2 and BMP4, can promote the posterior / hindgut fate and inhibit the foregut fate. In addition, BMP signaling regulates the formation of different regional types of intestine. Inhibition of BMPs with noggin after the hindgut stage promotes proximal intestinal fate (duodenum / jejunum). Activation of BMP signaling after the hindgut stage promotes more distal enterocyte fate (cecum / colon).

[0082] Activation of BMP can be carried out by contacting the mid / hindgut spheroids with BMP activators and EGF signaling pathway activators for a period of time sufficient to form the human colon organoid. The demarcation of the incubation period can be defined by the time point at which the human colon organoid type expresses SATB2. Personnel of ordinary skill in the art will readily understand suitable BMP activators and EGF signaling pathway activators. Suitable BMP activators may include, for example, BMP2, BMP4, BMP7, BMP9 and proteins or small molecule agonists such as ventromorphins (Genthe et al. 2017) or proteins used as agonists. BMP activators and EGF signaling pathway activators may be contacted with mid- / hindgut spheroids for about 1 day to about 3 days. BMP signaling can be activated within the first three days. In one aspect, the contact step of the BMP activator and the EGF signaling pathway activator is 24 hours to about 10 days, or about 48 hours to about 9 days, or about 3 days to about 8 days, or about 4 days to about 8 days, or about 5 days to about 7 days. Suitable EGF activators may include, for example, TGFα, HB-EGF, amphiregulin, Epigen, betacellulin, and small molecules such as db-cAMP. The EGF activator may be contacted with the mid- / hindgut spheroids at a concentration of about 10 ng / mL to 10,000 ng / ML for a period of about 24 hours to about 10 days, or about 48 hours to about 9 days, or about 3 days to about 8 days, or about 4 days to about 8 days, or about 5 days to about 7 days.

[0083] Mid / hindgut spheroids may be contacted with a BMP activator and / or an EGF activator at a concentration of 5 ng / ml or more; 20 ng / ml or more; 50 ng / ml or more; 75 ng / ml or more; 100 ng / ml or more; 120 ng / ml or more; 150 ng / ml or more; 200 ng / ml or more; 500 ng / ml or more; 1,000 ng / ml or more; 1,200 ng / ml or more; 1,500 ng / ml or more; 2,000 ng / ml or more; 5,000 ng / ml or more; 7,000 ng / ml or more; 10,000 ng / ml or more; or 15,000 ng / ml or more, alone or in combination. In some embodiments, the concentration of the signaling molecule remains constant throughout the treatment. In other embodiments, the concentration of the molecule of the signaling pathway changes during the treatment. In some embodiments, the signaling molecules according to the present invention are suspended in a culture medium comprising DMEM and fetal bovine serum serine (FBS). The FBS concentration may be 2% and higher; 5% and higher; 10% or higher; 15% or higher; 20% or higher; 30% or higher; or 50% or higher. One skilled in the art will appreciate that the protocols described herein are applicable to any known signaling pathway molecules described herein, either alone or in combination.

[0084] Examples

[0085] The following non-limiting examples are provided to further illustrate aspects of the present invention disclosed herein. It will be appreciated by those skilled in the art that the technical representatives disclosed in the following examples have been found to work well in the practice of the present invention and therefore can be considered as examples of patterns constituting its practice. However, it will be appreciated by those skilled in the art that, in light of the present disclosure, many changes may be made to the disclosed particular aspects and still the same or similar results may be obtained without departing from the spirit and scope of the present invention.

[0086] The epithelium of the gastrointestinal tract is derived from the definitive endoderm, which is one of the main germ layers established during gastrulation. The process of intestinal morphogenesis converts the definitive endoderm into a primitive intestinal tube with foregut, midgut and hindgut. The midgut produces a small proximal large intestine, and the hindgut produces a distal large intestine and rectum (Zorn and Wells, 2009). The small intestine is further subdivided into 3 segments: the duodenum, which participates in the absorption of nutrients and the uptake of iron, the jejunum, which participates in the digestion and absorption of nutrients, and the ileum, which participates in the absorption of bile acids and vitamin-B12 (Jeejeebhoy, 2002). The large intestine is subdivided into the cecum, colon and rectum, which are all involved in the absorption of water and electrolytes (Jeejeebhoy, 2002). Although recent progress has elucidated the development of the small intestine (Finkbeiner et al., 2015; Spence et al., 2011; Watson et al., 2014), little is known about the development of the human large intestine / colon. Furthermore, diseases affecting this region of the gastrointestinal (GI) tract, colitis, colon cancer, polyposis syndromes, and irritable bowel syndrome are prevalent (Molodecky et al., 2012; Siegel et al., 2014; Zbuk and Eng, 2007). Animal models of polyposis syndromes and colon cancer are limited because polyps and tumors preferentially form in the small intestine and rarely in the colon or rectum (Haramis et al., 2004; He et al., 2004; Moser et al., 1990).

[0087] The applicant has previously described a method in which human pluripotent stem cells can be differentiated into intestinal tissue by a directed differentiation step that approximates the development of small intestine embryos. First, by treating with activin A, pluripotent stem cells are differentiated into definitive endoderm. Definitive endoderm is exposed to high levels of Wnt and FGF to induce morphogenesis into mid / hindgut tube spheroids. Once formed, these midgut / hindgut spheroids, when grown in 3-dimensional cultures under conditions that are conducive to intestinal growth, transition through the stage of approximate in vivo small intestine development and form human intestinal organoids (HIO) (Spence et al., 2011). HIO has small intestinal properties and has been shown to be very useful for modeling small intestine biology (Bouchi et al., 2014; Finkbeiner et al., 2015; Watson et al., 2014; Xue et al., 2013). However, to date, PSC-derived large intestinal organoids have not yet been developed, and considering the prevalence of diseases in the large intestine, such systems will allow development and disease mechanisms to be interrogated in this area of ​​the gastrointestinal tract.

[0088] In order to develop a method for generating large intestinal organoids, the applicant first identified Satb2 as a definitive marker for the putative large intestinal epithelium in frogs, mice and humans. Using Satb2 as a marker, the applicant has shown that BMP signaling is required for the specialization of the hindgut endoderm of frogs and mice, which is consistent with the known role of BMP in posterior ventral development (Kumar et al., 2003; Roberts et al., 1995; Sherwood et al., 2011; Tiso et al., 2002; Wills et al., 2008). In addition, stimulating BMP signaling in PSC-derived intestinal tube cultures for 3 days is sufficient to induce the formation of colon organoids with posterior HOX codes and expression of SATB2. Human colon organoids (HCOs) have a marker spectrum and cell types consistent with the large intestine. In addition, HCOs, but not HIOs, form colonic enteroendocrine cells (EECs) in response to the expression of NEUROG3, proving that HCOs are functionally committed to the colon region. Furthermore, HCOs implanted under the renal capsule of immunocompromised mice and grown in vivo for 8-10 weeks maintained their regional identity, forming tissue with colonic morphology, containing colon-specific cell types, with proliferative and differentiation zones, and a well-formed smooth muscle layer. Enteroids and colonoids derived from in vivo grown organoids maintained regional identity. Finally, RNA-seq analysis showed that HIOs and HCOs underwent substantial maturation and expressed regional markers consistent with small and large intestinal identity, respectively. In summary, Applicants identified an evolutionarily conserved BMP-HOX pathway in frogs and mice and used it to direct hindgut patterning and formation of human colonic organoids.

[0089] result

[0090] SATB2 expression marks the intestinal endoderm of the posterior embryonic and adult intestine.

[0091] The molecular pathways that establish the midgut, hindgut, presumptive small intestine, and large intestine are poorly understood, in part due to a lack of well-defined markers. This limits the ability to direct human PSCs to differentiate into regionally distinct intestinal organoids, particularly large intestinal organoids. We therefore identified markers that distinguish distinct domains of the mouse embryonic gut and used them to interrogate signaling pathways that mimic the early intestine. Consistent with previous reports, we found that in e9.5 mouse embryos, Gata4 marks the intestinal endoderm from the posterior foregut to the yolk stalk ( Figure 8A)(Aronson et al., 2014; Battle et al., 2008; Beuling et al., 2008a; Beuling et al., 2007a; Beuling et al., 2007b; Beuling et al., 2010; Beuling et al., 2008b; Bosse et al., 2007; Kohlnhofer et al., 2016; Patankar et al., 2012a; Patankar et al., 2012b; Sherwood et al., 2009; Walker et al., 2014). At later stages of development (e11.5-e16.5), Gata4 continues to clearly mark the anterior but not the posterior intestine ( Figure 8 BD, IJ). This expression domain is expressed in mice (not shown) and humans ( Figure 8 KL) remain intact into adulthood.

[0092] To identify markers for the posterior fetal intestine, the applicant used public expression databases such as GNCProTM, TiGER and the Human Protein Atlas for colon-enriched genes (described in the Materials and Methods section) and found that Satb2 is a potential marker for the large intestine. Satb2 is a member of the CUT class of homeobox genes (Holland et al., 2007), which bind to the nuclear matrix attachment region and participate in chromatin remodeling (Gyorgy et al., 2008). Immunostaining showed that Satb2 protein was first detected in the posterior endoderm of mouse embryos at e9-9.5 and was associated with Gata4 ( Figure 8 A) Formation of discrete expression boundaries indicates that the Satb2+ domain marks the hindgut, a broader expression domain than previously identified (Dobreva et al., 2006). Satb2 expression continues to mark the hindgut endoderm throughout development (e11.5-16.5) Figure 8 B, C, E, F, H, J) and in mice (not shown) and humans ( Figure 8 L). Using published human proteome and RNA-seq data, the applicants demonstrated that GATA4 and SATB2 differentially mark the proximal and distal regions of the human fetal and adult intestine, respectively (Bernstein et al., 2010; Fagerberg et al., 2014)(Wang et al., 2015)( Fig. 9 AC). These data suggest that the Gata4 and Satb2 expression boundary is established early in mouse development and marks the future boundary of the developing small and large intestine in both mice and humans.

[0093] Satb2 expression in the embryonic hindgut endoderm requires BMP signaling

[0094] Applicants next used Satb2 as a marker to identify pathways that promote hindgut fate in the embryo. Applicants first determined whether BMP signaling was active in the hindgut tube, given its known role in patterning endoderm at several developmental stages in zebrafish, clawed frogs, chickens, and mice (Kumar et al., 2003; Roberts et al., 1995; Sherwood et al., 2011; Tiso et al., 2002; Wills et al., 2008). Applicants observed that BMP signaling was highly active in the endoderm and mesoderm of the hindgut tube of e8.5 mouse embryos, as measured by phosphorylated Smad1 / 5 / 8 (pSMAD1 / 5 / 8). Figure 1 To determine whether BMP signaling is required for patterning of the hindgut tube, we cultured early headfold stage mouse embryos (e7.5) in the presence of the BMP signaling inhibitor DMH-1 ( Figure 1 C). After 48 hours of DMH-1 treatment, we found that pSmad1 / 5 / 8 levels were significantly reduced and Satb2 expression was lost in the hindgut ( Figure 2 DK). In addition, Satb2 expression was lost in the first brachial arch of DMH-1 treated embryos, consistent with previous studies in zebrafish (Sheehan-Rooney et al., 2013). DMH-1 had no effect on TGFβ3 signaling as measured by pSmad2 / 3 levels ( Figure 1 F). Considering the evolutionary conservation of Satb2 in vertebrate species (Li et al., 2006), the applicants investigated whether Satb2 expression in the hindgut of frog embryos requires BMP ( Figure 2 L). Similar to mice, Xenopus embryos were treated with DMH-1 ( Figure 1 MV), or transgenic expression of the BMP-antagonist Noggin (not shown) resulted in loss of Satb2 expression in the hindgut and brachial arch. BMP signaling has been shown to directly regulate Satb2 expression in the mouse embryonic mandible through direct binding of Smad1 / 5 to a conserved enhancer (Bonilla-Claudio et al., 2012), suggesting that Satb2 may also be a direct BMP target in the intestine. Taken together, these results reveal a conserved pathway in vertebrates where BMP signaling is required to define the posterior majority of the developing gut tube that generates the distal ileum and large intestine.

[0095] BMP signaling promotes posterior fate in human intestinal tube cultures.

[0096] We next used human PSC-derived nascent CDX2+ gut spheroids as described previously (Spence et al., 2011) to investigate whether BMP signaling could be used to promote hindgut fate in humans. We used the BMP inhibitors NOGGIN or BMP2 to inhibit or activate BMP signaling, respectively. Figure 2 A), and BMP signaling levels were monitored by accumulation of nuclear pSMAD1 / 5 / 8. Control cultures had low levels of pSMAD1 / 5 / 8 protein, and addition of NOGGIN abolished this staining ( Figure 2 BD). In contrast, addition of BMP2 resulted in rapid accumulation of pSMAD158 in both epithelial and mesodermal cells, suggesting that both cell types respond to BMP signaling similarly to what the Applicants have observed in mouse embryos ( Figure 1 AB). The specificity of pSmad1 / 5 / 8 staining was confirmed using adult mouse colon, which showed that pSmad1 / 5 / 8 staining was confined to the differentiation compartment of the upper crypts ( Figure 2 E), as previously reported (Hardwick et al., 2004; van Dop et al., 2009; Whissell et al., 2014). Further analysis of organoids revealed that 3 days of BMP2 treatment was sufficient to induce high levels of SATB2 protein in the epithelium compared to NOGGIN and control cultures ( Figure 2 FI). This suggests that a short pulse of BMP activity is sufficient to pattern globular endoderm toward a hindgut tube fate.

[0097] While BMP signaling is known to regulate anterior-posterior patterning of the endoderm, little is known about the transcriptional networks that ultimately confer positional identity along the AP axis in mammals. Applicants used human gut spheroids and RNA-seq to identify how BMP signaling establishes the posterior domain in the developing human intestine. Principal component analysis revealed that gut spheroids treated with BMP for 3 days clustered separately from NOGGIN and control treated organoids ( Figure 2 J). Examination of gene ontology terms (GO terms) revealed that regulation of BMP signaling affects a variety of biological processes, including organ morphogenesis, cell-cell signaling, pattern specification, and cellular responses to BMP signaling ( Figure 2 K). The best-established regulators of AP patterning are HOX genes, and Applicants have found that BMP activation leads to downregulation of anterior HOX genes and upregulation of posterior HOX genes ( Figure 2 L). Specifically, Applicants observed BMP-mediated increases in multiple paralogs of groups HOX10, 11, 12, and 13. These results suggest that BMP signaling broadly regulates the AP hox code during patterning of the human gut and suggest a mechanism for the initial specialization of the distal gastrointestinal tract.

[0098] BMP signaling acts downstream of SHH to induce the posterior HOX code.

[0099] Previous studies have shown that Sonic Hedgehog (Shh) functions upstream of Bmp4 and Hox13 expression during hindgut patterning in the chicken embryo ( Fig.10 A)(Roberts et al., 1995). However, due to the embryonic lethality caused by overexpression of Bmp4 in the midgut and hindgut, the relative epistatic relationship between BMP and Hox13 has not been investigated ( Fig.10 B) (De Santa Barbara et al., 2005; Roberts et al., 1995). Applicants used human intestinal tube cultures to better model the epistatic relationship of SHH-BMP-HOX13 during hindgut tube patterning. Activation of hedgehog signaling with the smoothened agonist SAG resulted in concentration-dependent activation of the BMP signaling target gene MSX2 and the mesenchymal HOX factors HOXA13 and HOXD13 ( Fig.10 C). However, SAG-mediated activation of these factors is only a subset of BMP2-mediated activation ( Fig.10 C). Applicants further showed that the ability of HH signaling to activate HOXA13 is completely dependent on BMP ( Fig.10 DE), confirming that BMP signaling functions downstream of SHH, as previously reported (Shyer et al., 2015; Walton et al., 2012; Walton et al., 2009; Walton et al., 2016). It has not been determined whether BMP signaling is sufficient to activate the post-HOX program downstream of HH signaling. Therefore, Applicants examined BMP induction of HOXA13 in the presence of the SHH inhibitor cyclopamine and found that BMP2 was sufficient to induce HOXA13 when SHH signaling was inhibited ( Fig.10 FG). Consistent with this, activation of SHH signaling during BMP patterning did not improve SATB2 expression ( Fig.11 A). Experiments in Xenopus confirmed this epistatic relationship between SHH and BMP (data not shown), suggesting that this mechanism is evolutionarily conserved. Overall, Applicants' data indicate that BMP signaling is sufficient to activate the posterior HOX code and does so downstream of HH signaling.

[0100] BMP-derived organoids cultured in vitro retain distal properties.

[0101] We next investigated whether 3 days of BMP treatment was sufficient to confer stable regional identity after extended organoid culture for 25 days ( Figure 3ONGUT1 (a marker of the proximal small intestine) levels were highest in NOGGIN and control organoids but absent in BMP2-treated organoids ( Figure 3 AD). In contrast, SOGB2 was absent from the epithelium of NOGGIN- and control-treated organoids, but was ubiquitously expressed in nearly all CDX2+ epithelial cells of BMP2-treated organoids ( Figure 3 EH, Fig.11 A). Importantly, modulation of BMP signaling had similar proximal-distal patterning effects on multiple human PSC lines, including embryonic stem cell lines H1 and H9 and induced pluripotent stem cell lines (IPSC 54.1 and IPSC 72.3) (as shown below). Applicants frequently observed non-epithelial SATB2 expression in NOGGIN and control organoids (data not shown), likely due to the presence of other cell types known to be present in HIOs in vitro (Spence et al., 2011). Examination of HOXB13 and HOXD13, which are expressed in the posterior epithelium and mesenchyme, respectively, further revealed that BMP-treated organoids maintained posterior patterning after prolonged culture in vitro ( Fig.11 BC).

[0102] Goblet cells are distributed in a low to high gradient from the proximal small intestine to the distal large intestine (Rodriguez-Pineiro et al., 2013), and Applicants investigated whether goblet cell numbers were low in proximal organoids and high in distal organoids. MUC2 staining analysis at 28 days revealed that BMP2-treated organoids had high numbers of goblet cells, as visualized by intracellular MUC2 ( Figure 3 IL). Applicants further confirmed the regional nature of goblet cells using the marker MUC5B, which is expressed by a subset of goblet cells in the colon but not in the small intestine (van Klinken et al., 1998). MUC5B staining was absent in 28-day organoids treated with Noggin and controls, but was present in BMP2-treated organoids ( Figure 5 ). Goblet cell morphology becomes more mature in older organoids ( Fig.11 DI), where in 44-day-old BMP-treated organoids, Applicants observed goblet cells ( Fig.11 JL). The ability to visualize mucus secretion in BMP-treated organoids suggests that this organoid system can be used to study mucus secretion and the role of mucus in intestinal pathophysiology.

[0103] Although the regional pattern of organoids is stable after 28 days of culture, the applicant wants to investigate whether early patterning is fully established after the initial 3 days of treatment. To this end, the applicant transferred 3-day NOGGIN-treated spheroids to medium containing BMP2 for 3 days, and conversely transferred 3-day BMP-treated spheroids to medium containing NOGGIN for 3 days. Proximal organoids generated with NOGGIN did not express SATB2 in response to BMP2, demonstrating that proximal fate is stable after 3 days of patterning ( Fig.11 A). In the opposite experiment, while 3 days of BMP2 treatment was sufficient to induce a stable distal fate, a subset of organoids lost SATB2 expression in response to NOGGIN treatment ( Fig.11 A). Although 3 days of BMP2 treatment is sufficient to induce a stable colonic fate in vitro and in vivo ( Fig.12 ), but still retains plasticity in the early hindgut. This is consistent with the observation that the colonic endoderm of midgestation rat embryos is more regionally plastic than the small intestinal endoderm (Ratineau et al., 2003).

[0104] BMP signaling pathway patterns the mesenchyme in organoids.

[0105] Although stimulation of BMP signaling confers epithelial cell regional properties to organoids, the applicant also observed pSMAD1 / 5 / 8 in the non-epithelial compartments of BMP2-treated organoids during patterning, as well as upregulation of post-HOX factors known to be expressed in the mesenchyme. To determine whether mesenchymal patterning is stable, or whether continued patterning from epithelial input is required, the applicant isolated and expanded mesenchymal cell cultures for 2-3 weeks and analyzed their regional HOX gene expression. Mesenchymal cultures lack cells expressing E-cadherin, indicating that they are primarily composed of mesenchyme ( Figure 3 Q). Analysis of HOXD3, which is enriched in the proximal intestinal mesenchyme (Yahagi et al., 2004), demonstrated that mesenchyme from NOGGIN and control treated organoids had a stable proximal identity, whereas BMP treated organoids had reduced expression of HOXD3 ( Figure 3 R) and high levels of HOXA13 ( Figure 3 S), which continues to be expressed in human colonic fibroblasts (Higuchi et al., 2015). Collectively, these data suggest that early regulation of BMP signaling patterns both epithelium and mesenchyme, and that mesenchymal patterning is stable even in the absence of epithelium.

[0106] Induction of colonic enteroendocrine cells was restricted to BMP2-treated organoids.

[0107] The development of several ECC subtypes is regionally restricted to specific segments of the small and large intestine. For example, expression of the protein INSL5 is restricted to colonic EECs (Burnicka-Turek et al., 2012; Thanasupawat et al., 2013). As a functional test of colonic identity, the Applicants determined whether experimental induction of the colonic EEC marker INSL5 was restricted to distal organoids treated with BMP2. To this end, the Applicants used an iPSC line containing a doxycycline (DOX)-inducible NEUROG3 expression cassette to inducibly express the secretory transcription factor NEUROG3 ( Figure 4 A), as previously described (McCracken et al., 2017; McCracken et al., 2014). Applicants performed a 6-hour DOX pulse and observed robust induction of EECs measured by CHGA-positive cells after an additional 7 days in culture ( Figure 4 However, the Applicants observed INSL5-positive cells only in BMP2-treated organoids and confirmed this by QPCR analysis ( Figure 4 CH, J). Given that INSL5 expressing cells are exclusively in the colon, Applicants' data strongly suggest that BMP2 treated organoids are functionally committed to a colonic fate. Expression of distal markers such as SATB2, MUC5B and HOXA13 and the ability to generate colon specific ECCs support the conclusion that BMP2 treated organoids are colonic and will therefore be referred to as human colonic organoids (HCOs).

[0108] Maintaining regional identity of patterned organoids in vivo.

[0109] Previous studies in mouse and human fetal intestine have demonstrated that regional identity and tissue morphology of distinct regions of the intestine are maintained following orthotopic transplantation and growth in immunocompromised mice (Duluc et al., 1994; Savidge et al., 1995). To determine whether HIOs and HCOs patterned in vitro would maintain regional identity and grow into small and large intestinal tissue, Applicants transplanted them under the mouse renal capsule for 6-10 weeks, which Applicants have previously demonstrated results in maturation of HIOs into small intestinal tissue (Watson et al., 2014). Applicants observed that NOGGIN and control HIOs engrafted more efficiently than HCOs ( Fig.12 A). Consistent with their regional characteristics, transplanted HIO and HCO developed into mature tissues morphologically similar to the small or large intestine, respectively ( Figure 5 AE). The epithelium of NOGGIN and control organoids formed well-defined crypts and tall villi, comparable to the human small intestine. In contrast, BMP2-treated organoids contained crypts but lacked villi, similar to the colon.

[0110] In addition to their morphological similarities to the small or large intestine, transplanted HIOs and HCOs expressed distinct regional markers and contained regionally enriched cell types. For example, most of the epithelium of NOGGIN and control HIOs expressed the proximal marker GATA4 and did not express the large intestinal marker SATB2 ( Figure 5 FI, KN, Fig.12 BE). In contrast, HCO epithelial cells uniformly expressed SATB2+ but not GATA4 ( Figure 5 J,0, Fig.12 Furthermore, DEFA5-expressing Paneth cells were present in the crypts of NOGGIN and control HIOs, but not in HCOs similar to human colon ( Figure 5 PT, Fig.12 F) (Wehkamp et al., 2006). Applicants further confirmed the colonic nature of HCO using the colonic goblet cell marker MUC5B (van Klinken et al., 1998), which is expressed by a subset of goblet cells in HCO but is undetectable in NOGGIN or control HIO ( Figure 5 UY, Fig.12 G). In addition, the number of MUC2+ goblet cells in HCO was much higher than that in HIO, consistent with the abundance of goblet cells seen in the human colon ( Fig.12 HL). The presence of patterning markers, goblet cells expressing MUC5B, and the absence of Paneth cells all support the conclusion that the transplanted HCOs were colonic epithelial.

[0111] Mature HIO and HCO expression regions of enteroendocrine hormones in vivo.

[0112] At least 12 major EEC subtypes are found in different regions of the gastrointestinal tract, and the applicants analyzed HIOs and HCOs for the presence of regional EECs. Ghrelin and motilin were found to be primarily in the proximal intestine, and correspondingly these hormones were primarily expressed in NOGGIN and control HIOs, but not in HCOs ( Figure 6 AD). Similarly, GIP was found in NOGGIN and control HIO but not in HCO, and GIP was present in K cells of the small intestine but not in the colon ( Figure 6 EH). Applicants then examined the presence of distally enriched EECs in HCO by analyzing the expression of GLP-1 and PYY, which are more abundant in the colon. Applicants observed that GLP-1 and PYY cells were more numerous in HCO compared to HIO, and that the expression of preproglucagon and PYY was higher ( Figure 6IP). In addition, the Applicants found that the expression of the colon-specific hormone INSL5 (Burnicka-Turek et al., 2012; Thanasupawat et al., 2013) was only in HCO ( Figure 6 QT).

[0113] Analysis of stem and progenitor cells in HIO and HCO in vivo and in vitro.

[0114] To determine whether the in vitro derived HIOs and HCOs express markers of stem and progenitor cells, Applicants used the previously described H9-BAC-LGR5-eGFP transgenic line (McCracken et al., 2014; Watson et al., 2014). Examination of LGR5-eGFP expression in organoids revealed expression in broad epithelial domains at early e13.5 similar to the expression pattern in Lgr5-eGFP mice (Shyer et al., 2015) ( Fig.13 A, B, F, G, K, L). GFP expression was also evident outside the organoid epithelium, as determined by histology and FACS analysis, which revealed a population of GFP+EPCAM- cells (data not shown). In addition, Applicants examined the expression of SOX9, a marker for progenitor cells in the fetal and adult intestine, and found that it was expressed in the epithelium of HIOs and HCOs ( Fig.13 CE, HJ, M-0). These data indicate that embryonic / fetal intestinal progenitor cells marked by LGR5-eGFP and SOX9 exist in HIO and HCO in vitro.

[0115] During later stages of intestinal development, progenitor cells are restricted to the base of developing villi, where they will eventually contribute to intestinal stem cells (ISCs) in the crypts of Lieberkuhn. To determine whether the progenitor cells observed in vitro by the applicants would undergo this developmental transition, the applicants transplanted HIOs and HCOs and monitored LGR5-eGFP, SOX9, and KI67 proteins. After in vivo organoid maturation, the applicants observed that LGR5-eGFP, SOX9, and KI67 were restricted to the base of the presumptive crypts ( Fig.13 PX). In addition, SOX9 was also observed in the villi of HECs and in EECs in the cuffs of HCOs transplanted with colonic epithelium, consistent with SOX9 expression in these cell types. Given that Sox9 and Lgr5 mark intestinal and colonic stem cells that are capable of forming enteroids and colonoids in mice (Gracz et al., 2010; Ramalingam et al., 2012), Applicants investigated whether the epithelium of transplanted organoids could be isolated and used to generate enteroids and colonoids. Both HIOs and HCOs generated cultures of epithelial organoids that grew and could be passaged ( Fig.13In addition, HCO-derived epithelial cultures expressed colonic markers CKB, FXYD3, SATB2, and HOXB13, but not proximal small intestinal markers PDX1 or GATA4, suggesting that regional identity was maintained ( Fig.13 B'-D'). These data suggest that HIOs and HCOs grown in vivo contain both progenitor and stem cells.

[0116] Comprehensive transcriptional profiling of HIO and HCO.

[0117] To broadly interrogate the regional identity and maturation of HIOs and HCOs, we performed RNA-seq analysis of HIOs and HCOs grown in vivo and compared them to published datasets of human fetal and adult small and large intestine. Principal component analysis revealed that primary tissues isolated from adult and fetal intestine clustered together along the principal component 1 (PC1) axis, which accounted for 36.5% of the cumulative variation between samples ( Fig.14 A). GO analysis revealed that this variation was due to cell types present only in primary tissues but not in PSC-derived grafts. For example, 6 of the top 10 biological processes present in human primary tissues and absent in grafts were related to immune cells ( Fig.14 BC). The second principal component (PC2) accounted for 17.7% of the cumulative variation and separated the samples according to maturity ( Figure 7 A). This component revealed that the transplanted organoids were more mature than human fetal intestine and fetal colon, but less mature than adult colon and intestine. The third principal component (PC3) accounted for 6.7% of the cumulative variation and separated samples according to regional characteristics, and showed that HCO was more similar to the colon, while HIO clustered with the small intestine ( Figure 7 A). Interestingly, human fetal samples did not cluster based on regional identity (small intestine vs. colon), suggesting that these samples may not be cleanly separated from defined regions of the gastrointestinal tract.

[0118] Applicants next used a hypergeometric mean test to determine the probability that HIO and HCO share similar patterns of region-specific gene expression in the small intestine and colon ( Figure 7B). A total of 341 transcripts were expressed in the small intestine and NOGGIN-treated HIOs compared to the colon or BMP2-treated HCOs, a ratio that is unlikely (P = 1.5×10-143). Similarly, the gene set upregulated in control HIOs had highly significant similarity to the gene set upregulated in the adult small intestine relative to the adult colon (P = 2.5×10-203). In contrast, the gene set upregulated in HCOs was highly enriched for genes upregulated in the colon relative to the small intestine (P = 4.1×10-53 and P = 6.0×1073, respectively). This analysis concluded that HIO patterning is most similar to the human small intestine and HCO patterning is colonic. To further explore the nature of HIOs (NOG and control treated) and HCOs, Applicants performed differential expression analyses (adult small intestine vs. adult colon; HIO vs. HCO). Applicants generated a 4-way scatter plot which also showed that a high proportion of genes upregulated in the colon were also upregulated in HCO, and most genes upregulated in the small intestine were also upregulated in HIO ( Figure 7 B, Table 1). Finally, analysis of enriched biological processes revealed that adult colon and transplanted HCOs have highly active Wnt signaling and similar HOX codes. Collectively, these data demonstrate that Applicants have developed a robust method to differentiate PSCs into human colon tissue.

[0119] Table 1. Genes upregulated in the adult small intestine and colon are also upregulated in HIO and HCO, respectively. Column 1, commonly upregulated in NOGHIO vs. HCO and adult small intestine vs. adult colon, Column 2, commonly upregulated in control HIO vs. HCOs and adult small intestine vs. adult colon, Column 3, commonly upregulated in HCO vs. NOG HIO and adult colon vs. adult small intestine, Column 4, commonly upregulated in HCO vs. control HIO and adult colon vs. adult small intestine

[0120]

[0121]

[0122]

[0123]

[0124]

[0125]

[0126]

[0127]

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134]

[0135] discuss

[0136] Historically, the classification of foregut, midgut, and hindgut has been based on the development of the anterior and posterior hilum of the intestine and the origin of the mesenteric blood supply (Uppal et al., 2011). Alternative definitions of midgut and hindgut have been proposed, in which the midgut is the portion of the intestine that originates in front of the umbilicus and the hindgut originates from the posterior portion of the umbilicus (Johnston, 1913; Savin et al., 2011). In either case, the historical reliance on anatomical landmarks, as well as the lack of more precise molecular markers to distinguish the anterior, mid, and hindgut, has made it difficult to develop methods to generate these cells / tissues in vitro from PSCs. Therefore, it is essential to identify markers that clearly demarcate the developing midgut and hindgut regions.

[0137] Applicants used a combination of CDX2, GATA4, ONECUT1 and SATB2 to identify the establishment of different molecular boundaries in the early stages of midgut and hindgut development in Xenopus, mice and humans. Interestingly, GATA4 and SATB2 expression domains form a boundary in the yolk stalk / presumed umbilical cord of mice and maintain this boundary throughout development and in the adult intestine. GATA4 expression marks the intestine in front of the umbilicus, while SATB2 expression marks the area behind the umbilicus, indicating that the umbilicus is the boundary between the midgut and hindgut (Johnston, 1913; Savin et al., 2011).

[0138] While ONECUT1 expression and SATB2 expression in HIOs are consistent with the proximal and distal nature of HIOs, respectively, GATA4 expression in proximal HIOs in vitro is not as robust as expected from its embryonic expression (data not shown). In contrast, GATA4 is robustly expressed after in vivo maturation of HIOs and in enteroids generated from patient biopsies (data not shown). This may indicate that factors involved in GATA4 expression are not present under culture conditions or that in vivo maturation is required for GATA4 epithelial expression. The data also suggest that high levels of GATA4 expression may be dispensable for early regionalization of the intestine, consistent with intestinal Gata4 knockout mice that maintain normal Onecut factor expression (Battle et al., 2008). In addition, a small fraction of BMP-treated organoids lost CDX2 expression and activated expression of bladder markers Keratin 13 and Uroplakin 1a (data not shown). This is consistent with BMP organoids having a hindgut fate, as urothelial tissue is derived from the hindgut / cloaca (Georgas et al., 2015).

[0139] SATB2 is expressed throughout the development of the distal ileum and large intestine, but it is not known whether SATB2 is required for distal intestinal development. Mouse knockout studies have focused on craniofacial and cortical neuron development, as mutations in SATB2 are associated with 2q32-q33 deletions and cleft palate associated with Glass syndrome (FitzPatrick et al., 2003). However, there is indirect evidence that SATB2 may play a role in human colon physiology. SATB2 has been identified as a susceptibility gene for ulcerative colitis in genome-wide association studies (McGovern et al., 2010). In addition, loss of SATB2 expression has been shown to be associated with poor prognosis in patients with colorectal cancer (Eberhard et al., 2012). Future studies using HCO may allow identification of SATB2 targets in the developing colon, which could provide insight into the pathology of ulcerative colitis and colorectal cancer.

[0140] Some studies in model organisms have involved BMP signaling pathways in patterning endoderm during hindgut development (Kumar et al., 2003; Roberts et al., 1995; Sherwood et al., 2011; Tiso et al., 2002; Wills et al., 2008). Consistent with this, applicants have demonstrated that posterior patterning of human definitive endoderm depends on BMP signaling, because inhibition of BMP eliminates the ability of WNT and FGF to promote posterior endoderm fate (McCracken et al., 2014). However, it is not surprising that BMP signaling plays other temporally different roles during intestinal development. For example, after establishing the proximal-distal regional domain, BMP signaling plays a role in establishing the crypt-villus axis in the intestine and colon (Li, 2005). Thus, the temporal requirement for patterning allows the embryo to use the same signaling pathway for multiple purposes in intestinal development, as has been reported in the Drosophila midgut (Driver and Ohlstein, 2014; Guo et al., 2013). In the context of human disease, mutations in BMPR1A are associated with a subset of patients with juvenile polyposis syndrome. The HCO system is well suited to identify HOX codes downstream of BMPs during early development, and it may be interesting to determine whether hamartomatous polyps with BMPR1A mutations have altered HOX gene expression.

[0141] Applicants have previously reported the in vitro directed differentiation and in vivo transplantation of HIOs (Spence et al., 2011; Watson et al., 2014), which are the small intestine. Given the unique physiological and pathological conditions that affect the large intestine, it is imperative to develop a colon model system to ask pathophysiological questions that are unique to the colon. In terms of development, this system provides the opportunity to study fundamental questions about how regional identity is established. HIOs and HCOs form unique cell types, such as Paneth cells in HIOs and colon-specific goblet cells in HCOs. In addition, HIOs and HCOs have a differentiated set of EECs that are typically enriched in the small and large intestines, respectively. Regionalized organoids should provide a platform for future studies of how different regions of the intestine generate regionalized stem cells. In addition, the generation of HCOs will allow for the modeling of diseases that affect the colon, such as ulcerative colitis and colorectal cancer.

[0142] Materials and methods

[0143] Animals. Immunodeficient NOD-SCID IL-2Rynu" (NSG) mice aged 8-16 weeks were used for transplantation experiments (obtained from the Comprehensive Mouse and Cancer Core Facility, Cincinnati, Ohio). Wild-type mice were used to study the mouse fetal intestine. All mice were housed in the animal facility of Cincinnati Children's Hospital Medical Center (CCHMC). All experiments were performed with the approval of the Institutional Animal Care and Use Committee of CCHMC.

[0144] BMP inhibition in frog and mouse embryos. Xenopus tropicalis embryo culture and small molecule treatments were performed as previously described (Rankin et al., 2012; Rankin et al., 2015). DMH-1 (Sigma D8946) was dissolved in DMSO and used at a final concentration of 20 pM; an equal concentration of DMSO vehicle was used on sibling embryos. Inhibitor treatment experiments were repeated twice with similar effects on the markers analyzed. For Xenopus in situ hybridization analysis, DIG-labeled antisense RNA probes were generated using linearized full-length cDNA plasmid templates (X. tropicalis satb2 was purchased from ATCC, clone 7720194; HinDIII, T7 were used for probes; X. laevis satb2 was a gift from Tyler Square and Daniel Medeiros, University of Colorado-Boulder; Xbal, Sp6 were used for probes.) Complete details describing probe synthesis and in situ hybridization protocols are available on Xenbase (hftp: / / wiki.xenbase.orq / xenwiki / index.php / Protocols).

[0145] For mouse whole embryo cultures, e7.5 embryos were cultured in a 1:1 mixture of Ham's F12 medium and whole embryo culture rat serum (Harlan Labs) containing N-2 supplement (Invitrogen). The vessels were placed on a roller culture apparatus (BTC Engineering, Cambridge, UK) and maintained at 37°C for 2 days and aerated with 20% O2 and 5% CO2. BMP signaling was inhibited by treatment with 5 pM DMH-1, with DMSO used as a vehicle control.

[0146] Human midgut / hindgut spheroids were generated. Human intestinal organoids were generated and maintained as previously described (Watson et al., 2014). Human embryonic stem cells and induced pluripotent stem cells were grown in six-well Nunclon surface plates (Nunc) coated with Matrigel (basement membrane matrix, BD Biosciences) under feeder-free conditions and maintained in mTESR1 medium (Stem Cell Technologies). To induce definitive endoderm (DE), human ES or iPS cells were passaged with Accutase (Invitrogen) and seeded at a density of 100,000 cells per well in Nunclon surface 24-well plates coated with Matrigel. For Accutase-divided cells, 10 pM Y27632 compound (Sigma) was added to the culture medium on the first day. After the first day, the culture medium was replaced with mTESR1 and the cells were grown for another 24 hours. The cells were then treated with 100 ng / mL Activin A for 3 days as previously described (Spence et al., 2011). DE were then treated with hindgut induction medium (RPMI1640, 2 mM L-glutamine, 2% decomplemented FBS, penicillin-streptomycin and 100 ng / mL activin A) for 4 days and treated with 500 ng / mL FGF4 (R&D) and 3 pM Chiron99021 (Tocris) to induce the formation of mid-hindgut spheroids.

[0147] The midgut / hindgut spheroids were patterned as HIO and HCO. Spheroids were collected from 24-well plates and seeded in Matrigel (BD). In order to produce proximal HIO, spheroids were covered with intestinal growth medium (Advanced DMEM / F-12, N2, B27, 15mM HEPES, 2mM L-glutamine, penicillin-streptomycin) supplemented with 100ng / mL EGF (R&D) or 100ng / mL EGF and 100ng / ml NOGGIN (R&D). In order to produce HCO, spheroids were covered with 100ng / mL EGF plus 100ng / mL BMP (R&D). For SHH experiments, 1pM SAG (Tocris), 5pM SAG or 2.5pM cyclopamine (Tocris) were added to the control medium for the first 3 days, and RNA samples were collected afterwards. Culture medium was changed at 3 days, and only EGF remained in the culture medium for all patterning conditions. Culture medium was then changed twice a week. HIOs and HCOs were re-seeded in fresh Matrigel every 14 days.

[0148] Generation of NEUROGENIN3 inducible lines. To generate doxycycline-inducible NEUROG3 lines, the applicant transduced IPSC 72.3 cells with pINDUCER21-NEUROG3 lentivirus and selected with 250g / mL of G418. Both the IPSC72.3 cell line and the inducible NEUROG3 have been described previously (McCracken et al., 2014). Stably transduced cells were differentiated into mid / hindgut spheroids and then patterned into HIO or HCO. The spheroids were grown for 28 days and pulsed with 0.5ug / mL doxycycline for 8 hours. On day 35, organoids were collected and analyzed by QPCR and IF.

[0149] Growth of organoid mesenchyme. Mesenchymal cells from organoids attached to the bottom of 24-well plates attached and grew in 2 dimensions. To expand mesenchymal cells from organoids, DMEM 10% FBS + L-glutamine + penicillin-streptomycin was added to the wells where organoids were harvested at 14 days. The medium was changed twice a week for a total of 2-3 weeks until close to 100% confluence was reached.

[0150] Transplantation of human intestinal organoids. NSG mice were maintained on an antibiotic diet (275 ppm sulfamethoxazole and 1,365 ppm trimethoprim; test diet). Food and water were provided ad libitum before and after surgery. Single HIOs were removed from Matrigel, matured in vitro for 28 days, washed with cold phosphate-buffered saline (DPBS; Gibco), and embedded in purified type I collagen (rat tail collagen; BD Biosciences) 12 hours before surgery to allow for the formation of solidified gel plugs. These plugs were then placed in standard growth medium (Advanced DMEM / F-12, B27, 15 mM HEPES, 2 mM L-glutamine, penicillin-streptomycin) supplemented with 100 ng / mL EGF (R&D) overnight. HIOs were then transplanted under the renal capsule as previously reported (Watson et al., 2014). Briefly, mice were anesthetized with 2% inhaled isoflurane (Butler Schein), and the left side of the mice was prepared aseptically with isopropyl alcohol and povidone iodine. A small left posterior subcostal incision was made to expose the kidney. A subcapsular pouch was created, and the collagen-embedded HIO was then placed in the pouch. The kidney was then returned to the peritoneal cavity and mice were given IP flushing Zosyn (100 mg / kg; Pfizer Inc.). The skin was closed in a double layer, and mice were injected subcutaneously with Buprenex (0.05 mg / kg; Midwest Veterinary Supply). At 8-10 weeks after implantation, the mice were then humanely euthanized or further experiments were performed.

[0151] Tissue processing, immunofluorescence, and microscopy. Tissues were fixed in 4% paraformaldehyde (PFA) on ice for 1-3 hours, depending on the size of the tissue. Organoids and transplant implants were frozen in OCT. OCT sections were blocked with donkey serum (5% serum in 1X PBS plus 0.5% Triton-X) for 30 minutes and incubated with primary antibodies overnight at 4°C. Slides were then washed 3 times with 1X PBS plus 0.5% Triton-X and incubated in secondary antibodies with DAPI in blocking buffer for 2 hours at room temperature. See Table 2 for a list of antibodies and corresponding dilutions. Slides were then washed 2 times with 1X PBS plus 0.5% Triton-X, followed by a final wash in 1X PBS. The slides were then incubated with (SouthernBiotech) coverslips were mounted. Images were captured on a Nikon Al confocal microscope and analyzed using Imaris imaging software (Bitplane). For overall staining, tissues were processed similarly as above and then cleared in Murray solution. Imaging was performed using a Nikon Al confocal microscope.

[0152] Table 2. QPCR primers used. Figure 3 and 4 .

[0153]

[0154]

[0155] Quantification of immunofluorescence images.Complete the image quantification of whole embryo by dividing the image into separated channels and then using ImageJ (NIH) to measure pixel area.Determine the pixel area of ​​each channel, determine the ratio between the channels, and the ratio of the embryo treated by control is expressed as 100.As explained above, the quantification of the organoid grown in vitro and in vivo is carried out on the slice of captured image.Use the spot function in [marls after calibration with human biopsy sample to quantify the quantity of CDX2, GATA4 and SATB2 positive nuclei.

[0156] RNA isolation and QPCR. RNA was extracted using an RNA extraction kit (Macharey-Nagel) and reverse transcribed into cDNA using Superscript VILO (Invitrogen) according to the manufacturer's protocol. QPCR primers were designed using the qPrimerDepot web tool (primerdepot.nci.nih.gov). Primer sequences are listed in Table 3. QPCR was performed using the QIAQUICK® Green PCR Kit (Qiagen) and the QuantStudio™ 6Flex Real-Time PCR System (Applied Biosystems).

[0157] Table 3. Antibodies used. Figure 1-6 .

[0158]

[0159] Identification of SATB2 as a large intestine marker.

[0160] In order to identify the markers of the large intestine, the applicant first used GNCPro http: / / gncpro.sabiosciences.comigncpro / expression_grapherphp to identify the transcription factors that were upregulated in the colon (compared to other tissues) based on the University of Tokyo database. Based on this search, SATB2 was the sixth-ranked gene in the colon. In order to confirm that SATB2 was indeed upregulated in the colon, the applicant used the TiGER database (hftp: / / bioinfo.wilmer.ihu.edu / tiger / db gene / SATB2-index.html) to search for SATB2 expression. In order to further confirm the expression of SATB2 in the colon and to examine the protein expression in various tissues, the applicant used the human protein atlas (http: / / www.proteinatlas.org / search / satb2). Similar methods were used to identify other markers of the large intestine / colon.

[0161] Public RNA-seq accession numbers. Download adult small and large intestine RNA-seq data from the public database E-MTAB-1733. These datasets represent whole organ tissues, including epithelial and muscle layers. Accession numbers for small intestine samples: ERR315344, ERR315381, ERR315409, ERR315442, ERR315461. Accession numbers for large intestine samples: ERR315348, ERR315357, ERR315484. Fig. 9B, Processed FPKM data were downloaded from https: / / qithub.com / hilldr / Finkbeiner StemCellReports2015. These data include the adult duodenum (ERS326992, ERS326976) and small intestine samples listed above from E-MTAB-1733 and human fetal intestine (also whole organ) samples from GSE18927. The accession numbers for human fetal small intestine are GSM1059508, GSM1059521, GSM1059486, GSM1059507, GSM1059517, GSM1220519. Fig. 9 C, data were obtained from GEO accession number GSE66749 platform GLP5175. The following samples were used: GSM1385160, GSM1385161, GSM1385162, GSM1385163, GSM1385164, GSM1385165, GSM1385166, GSM1385167, GSM1385168, GSM1385169, GSM1385170, GSM1385171, GSM1614646, GSM1614646. Sample values ​​were determined using the GEO2R "profile plot" function and searching for GATA4 and SATB2 by their ID numbers (3086100 and 2594089, respectively).

[0162] RNA-seq sequence assembly abundance estimation.Using Illumina HiSeq2500 platform, RNA library construction and RNA sequencing were performed by Cincinnati Children's Hospital DNA Sequencing Core.The quality of Illumina sequencing run was evaluated by analyzing the FASTQ data of each sample using FastQC version 0.10.1http: / / www.bioinformatics.babraham.ac.uk / projects / fastqc to identify the features of data that may indicate quality problems (e.g., low quality scores, over-represented sequences, inappropriate GC content, etc.).QC analysis did not find major problems.Applicants used software package Tuxedo Suite for comparison, differential expression analysis and post-analysis diagnosis.In brief, applicants used TopHat version 2.0.13 and Bowtie version 2.2.5 (Langmead et al., 2009) to compare readings to the reference transcriptome (UCSC hg19). Applicants used default parameter settings for alignment, except for "-b2-very-sensitive" to maximize the accuracy of read alignment, and "-no-coverage-search" and "-no-novel-juncs" to restrict read mapping to known transcripts. Cufflinks version 2.2.1 (Trapnell et al., 2012) was used for RNA abundance estimation. UCSC hgl9.fa was used as the reference genome sequence, and UCSC hgl9.gtf was used for transcriptome annotation. Applicants applied the following parameters in Cufflinks: "-multi-read-correct" to adjust expression calculations for reads mapped in multiple loci, and "-compatible-hits-norm" and "-upper-quartile-norm" were used to normalize expression values. The normalized FPKM table was generated using the CuffNorm function. RNA sequence assembly and transcript analysis were performed using a 64-bit Debian Linux stable version 7.10 (“Wheezy”) platform.

[0163] Differential expression analysis.

[0164] All figures and statistical analyses were performed in R version 3.3.1 (2016-06-21). Figures were generated using the R package ‘ggplot2’ (Ginestet, 2011). Differential expression analysis and statistical tests on Cufflinks output were done with the R package ‘SeqRetriever’ ‘SeqRetriever’ version 0.6 https: / / github.com / hilldr / SeqRetrieyer. Hypergeometric mean tests were used to assess the relative enrichment of shared gene expression features between groups using the R package ‘GeneOverlap’ http: / / shenlab-sinai.cithub.io / shenlab-sinai / . The complete RNA-seq FASTQ processing pipeline and analysis scripts are available at https: / / qithub.com / hilldr / Munera2016.

[0165] References

[0166] Aronson, BE, Aronson, SR, Berkhout, RP, Chavoushi, SF, He, A., Pu, WT, Verzi, MP, and Rasinski, SD (2014). GATA4 represses an ileal program of gene expression in the proximal small intestine by inhibiting the acetylation of histone H3, lysine 27. Bba-Gene RegulMech 1839, 1273-1282.

[0167] Battle, MA, Bondow, BJ, Iverson, MA, Adams, SJ, Jandacek, RJ, Tso, P. and Duncan, SA (2008). GATA4 is essential for jejuna function in mice. Gastroenterology 135, 1676-1686e1671.

[0168] Bernstein, BE, Stamatoyannopoulos, JA, Costello, JF, Ren, B., Milosavljevic, A., Meissner, A., Kellis, M., Marra, MA, Beaudet, AL, Ecker, JR, et al. (2010). The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol 28, 1045-1048.

[0169] Beuling, E., Bosse, T., aan de Kerk, DJ, Piaseckyj, CM, Fujiwara, Y., Katz, SG, Orkin, SH, Grand, RJ and Krasinski, SD (2008a). GATA4 mediates gene repression in the mature mouse small intestine through interactions with friend of GATA(FOG) cofactors. Dev Biol 322, 179-189.

[0170] Beuling, E., Bosse, T., Buckner, MA, and Krasinski, SD (2007a). Co-localization of Gata4 and Hnfl alpha in the gastrointestinal tract is restricted to the distal stomach and proximal small intestine. Gastroenterology 132, A586-A586.

[0171] Beuling, E., Bosse, T., de Kerk, DA, Piaseckyj, CM, Fujiwara, Y., Orkin, SH and Krasinski, SD (2007b). Fog cofactors partially mediate Gata4 function in the adult mouse small intestine. Gastroenterology 132, A692-A693.

[0172] Beuling, E., Kerkhof, IM, Nicksa, GA, Giuffrida, MJ, Haywood, J., aan deKerk, DJ, Piaseckyj, CM, Pu, WT, Buchmiller, TL, Dawson, PA, et al. (2010). Conditional Gata4 deletion in mice induces bile acid absorption in the proximal small intestine. Gut 59, 888-895.

[0173] Beuling, E., Kerkhof, IM, Piaseckyj, CM, Dawson, PA., Pu, WT, Grand, RJ, and Krasinski, SD (2008b). The absence of GATA4 in the distal small intestine defines the ilea! phenotype. Gastroenterology 134, A83-A84.

[0174] Bonilla-Claudio, M., Wang, J., Bai, Y., Klysik, E., Selever, J., and Martin, J. F. (2012). Bmp signaling regulates a dose-dependent transcriptional program to control facial skeletal development. Development, 139, 709-719.

[0175] Bosse, T., Fialkovich, JJ, Piaseckyj, CM, Beuling, E., Broekman, H., Grand, RJ, Montgomery, RK and Krasinski, SD (2007). Gata4 and Hnflalpha are partially required for the expression of specific intestinal genes during development. Am J Physiol Gastrointest Liver Physiol 292, G1302-1314.

[0176] Bouchi, R., Foo, KS, Hua, H., Tsuchiya, K., Ohmura, Y., Sandoval, P.R., Ratner, L.E., Egli, D., Leibel, R.L., and Accili, D. (2014). FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures. Nat Commun 5, 4242.

[0177] Burnicka-Turek, 0., Mohamed, BA, Shirneshan, K., Thanasupawat, T., Hombach-Klonisch, S., Klonisch, T., and Adham, IM (2012). INSL5-deficient mice display an alteration in glucose homeostasis and an impaired fertility. Endocrinology 153, 4655-4665.

[0178] De Santa Barbara, P., Williams, J., Goldstein, A. M., Doyle, A. M., Nielsen, C., Winfield, S., Faure, S., and Roberts, D. J. (2005). Bone morphogenetic protein signaling pathway plays multiple roles during gastrointestinal tract development. Developmental Dynamics: An Official Publication of the American Association of Anatomists, 234, 312-322.

[0179] Dobreva, G., Chahrour, M., Dautzenberg, M., Chirivella, L., Kanzler, B., Farinas, I., Karsenty, G., and Grosschedl, R. (2006). SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell 125, 971-986.

[0180] Driver, I. and Oh!stein, B. (2014). Specification of regional intestinal stem cell identity during Drosophila metamorphosis. Development 141, 1848-1856.

[0181] Duluc, I., Freund, JN, Leberquier, C. and Kedinger, M. (1994). Fetal endoderm primarily holds the temporal and positional information required for mammalian intestinal development. J Cell Biol 126, 211-221.

[0182] Eberhard, J., Gaber, A., Wangefjord, S., Nodin, B., Uhlen, M., Ericson Lindquist, K. and Jirstrom, K. (2012). A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer 106, 931-938.

[0183] Fagerberg, L., Hallstrom, BM, Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 13, 397-406.

[0184] Finkbeiner, SR, Hill, DR, Altheim, CH, Dedhia, PH, Taylor, MJ, Tsai, YH, Chin, AM, Mahe, MM, Watson, CL, Freeman, JJ, et al. (2015). Transcriptome-wide Analysis Reveals Hallmarks of Human Intestine Development and Maturation In Vitro and InVivo. Stem Cell Reports.

[0185] FitzPatrick, DR, Carr, IM, McLaren, L., Leek, JP, Wightman, P., Williamson, K., Gautier, P., McGill, N., Hayward, C., Firth, H., et al. (2003). Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum Mol Genet 12, 2491-2501.

[0186] Georgas, KM, Armstrong, J., Keast, JR, Larkins, CE, McHugh, KM, Southard-Smith, EM, Cohn, MJ, Batourina, E., Dan, H., Schneider, K., et al. (2015). An illustrated anatomical ontology of the developing mouse lower urogenital tract. Development 142, 1893-1908.

[0187] Ginestet, C. (2011). ggplot2: Elegant Graphics for Data Analysis. JR Stat Soc aStat 174, 245-245.

[0188] Gracz, AD, Ramalingam, S. and Magness, ST (2010). Sox9 expression marks a subset of CD24-expressing small intestine epithelial stem cells that form organoids invitro. Am J Physiol-Gastr L 298, G590-G600.

[0189] Guo, Z., Driver, I., and Ohlstein, B. (2013). Injury-induced BMP signaling negatively regulates Drosophila midguthomeostasis. Journal of Cell Biology, 201, 945-961.

[0190] Gyorgy, AB, Szemes, M., de Juan Romero, C., Tarabykin, V. and Agoston, DV (2008). SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons. Eur J Neurosci 27, 865-873.

[0191] Haramis, APG, Begthel, H., van den Born, M., van Es, J., Jonkheer, S., Offerhaus, GJA and Clevers, H. (2004). De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science, 303, 1684-1686.

[0192] Hardwick, JC, Van Den Brink, GR, Bleuming, SA, Ballester, I., Van Den Brande, JM, Keller, JJ, Offerhaus, GJ, Van Deventer, SJ and Peppelenbosch, MP (2004). Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126, 111-121.

[0193] He, XC, Zhang, JW, Tong, WG, Tawfik, 0., Ross, J., Scoville, DH, Tian, ​​Q., Zeng, X., He, X., Wiedemann, LM, et al. (2004). BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nature Genetics 36, 1117-1121.

[0194] Higuchi, Y., Kojima, M., Ishii, G., Aoyagi, K., Sasaki, H., and Ochiai, A. (2015). Gastrointestinal Fibroblasts Have Specialized, Diverse Transcriptional Phenotypes: A Comprehensive Gene Expression Analysis of Human Fibroblasts. Plos One 10.

[0195] Holland, PWH, Booth, HAF and Bruford, EA (2007). Classification and nomenclature of all human homeobox genes. Bmc Biol 5.

[0196] Jeejeebhoy, KN (2002). Short bowel syndrome: a nutritional and medical approach. CMAJ 166, 1297-1302.

[0197] Johnston, TB (1913). Extroversion of the Bladder, complicated by the Presence of Intestinal Openings on the Surface of the Extroverted Area. J Anat Physiol 48, 89-106.

[0198] Kohlnhofer, BM, Thompson, CA, Walker, EM, and Battle, MA (2016). GATA4 regulates epithelial cell proliferation to control intestinal growth and development in mice. Cell Mol Gastroenterol Hepatol 2, 189-209.

[0199] Kumar, M., Jordan, N., Melton, D., and Grapin-Botton, A. (2003). Signals from lateral plate mesoderm instructendoderm toward a pancreatic fate. Dev Biol 259, 109-122.

[0200] Langmead, B., Trapnell, C., Pop, M. and Salzberg, SL (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10, R25.

[0201] Li, H., Coghlan, A., Ruan, J., Coin, L. J., Heriche, J. K., Osmotherly, L., Li, R., Liu, T., Zhang, Z., Bolund, L., et al. (2006). TreeFam: a curated database of phylogenetic trees of animal gene families. Nucleic Acids Res, 34, D572-580.

[0202] Li, LH (2005). BMP signaling inhibits intestinal stem cell self-renewal through antagonizing Wnt signaling. Gastroenterology 128, A702-A702.

[0203] McCracken, KW, Aihara, E., Martin, B., Crawford, CM, Broda, T., Treguier, J., Zhang, X., Shannon, JM, Montrose, MH and Wells, JM (2017). Wnt / beta-catenin promotes gastric fundus specification in mice and humans. Nature 541, 182-187.

[0204] McCracken, KW, Cata, EM, Crawford, CM, Sinagoga, KL, Schumacher, M., Rockich, BE, Tsai, YH, Mayhew, CN, Spence, JR, Zavros, Y., et al. (2014). Modeling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516, 400-404.

[0205] McGovern, DP, Gardet, A., Torkvist, L., Goyette, P., Essers, J., Taylor, KD, Neale, BM, Ong, RT, Lagace, C., Li, C., et al. (2010). Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genetics 42, 332-337.

[0206] Molodecky, NA., Soon, I. S., Rabi, DM, Ghali, WA, Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., et al. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54e42; quiz e30.

[0207] Moser, AR, Pitot, HC and Dove, WF (1990). A Dominant Mutation That Predisposes to Multiple Intestinal Neoplasia in the Mouse. Science 247, 322-324.

[0208] Patankar, J., Obrowsky, S., Hoefler, G., Battle, M., Kratky, D., and Levak-Frank, S. (2012a). Intestinal Deficiency of Gata4 Protects from Diet-Induced Hepatic Steatosis by Suppressing De Novo Lipogenesis and Gluconeogenesis in Mice. J Hepatol 56, S496-S496.

[0209] Patankar, J. V., Obrowsky, S., Doddapattar, P., Hoefler, G., Battle, M., Levak-Frank, S., and Kratky, D. (2012b). Intestinal GATA4 deficiency protects from diet-induced hepatic steatosis. Journal of Hepatology 57, 1061-1068.

[0210] Ramalingam, S., Daughtridge, GW, Johnston, MJ, Gracz, AD, and Magness, ST (2012). Distinct levels of Sox9 expression mark colon epithelial stem cells that form colonoids in culture. Am J Physiol Gastrointestinal and Liver Physiol 302, G10-20.

[0211] Rankin, S. A., Gallas, A. L., Neto, A., Gomez-Skarmeta, J. L., and Zorn, A. M. (2012). Suppression of Bmp4 signaling by the zinc-finger repressors Osrl and Osr2 is required for Wnt / beta-catenin-mediated lung specification in Xenopus. Development, 139, 3010-3020.

[0212] Rankin, S. A., Thi Tran, H., Wlizla, M., Mancini, P., Shifley, E. T., Bloor, S. D., Han, L., Vleminckx, K., Wert, S. E., and Zorn, A. M. (2015). A molecular atlas of Xenopus respiratory system development. Developmental Dynamics: An Official Publication of the American Association of Anatomists, 244, 69-85.

[0213] Ratineau, C., Duluc, I., Pourreyron, C., Kedinger, M., Freund, JN and Roche, C. (2003). Endoderm- and mesenchyme-dependent commitment of the differentiated depithelial cell types in the developing intestine of rat. Differentiation 71, 163-169.

[0214] Roberts, DJ, Johnson, RL, Burke, AC, Nelson, CE, Morgan, BA and Tabin, C. (1995). Sonic Hedgehog Is an Endodermal Signal Inducing Bmp-4 and Hox Genes during Induction and Regionalization of the Chick Hindgut. Development 121, 3163-3174.

[0215] Rodriguez-Pineiro, AM, Bergstrom, JH, Ermund, A., Gustafsson, JK, Schutte, A., Johansson, ME, and Hansson, GC (2013). Studies of mucus in mouse stomach, small intestine, and colon. II. Gastrointestinal mucus proteome reveals Muc2 and Muc5ac accompanied by a set of core proteins. Am J Physiol Gastrointestinal Liver Physiol 305,

[0216] Savidge, TC, Morey, AL, Ferguson, DJ, Fleming, KA, Shmakov, AN and Phillips, AD (1995). Human intestinal development in a severe-combined immunodeficient xenograft model. Differentiation 58, 361-371.

[0217] Savin, T., Kurpios, NA, Shyer, AE, Florescu, P., Liang, H., Mahadevan, L. and Tabin, CJ (2011). On the growth and form of the gut. Nature 476, 57-62.

[0218] Sheehan-Rooney, K., Swartz, ME, Lovely, CB, Dixon, MJ, and Eberhart, JK (2013). Bmp and Shh signaling mediate the expression of satb2 in the pharyngeal arches. PLoS One 8, e59533.

[0219] Sherwood, RI, Chen, TY and Melton, DA (2009). Transcriptional dynamics of endodermal organ formation. Developmental Dynamics: An Official Publication of the American Association of Anatomists 238, 29-42.

[0220] Sherwood, RI, Maehr, R., Mazzoni, EO and Melton, DA (2011). Wnt signaling specifies and patterns intestinal endoderm. Mechanisms of Development 128, 387-400.

[0221] Shyer, AE, Huycke, TR, Lee, C., Mahadevan, L., and Tabin, CJ (2015). Bending gradients: how the intestinal stem cell gets its home. Cell, 161, 569-580.

[0222] Siegel, R., Desantis, C. and Jemal, A. (2014). Colorectal cancer statistics, 2014. CA Cancer J Clin 64, 104-117.

[0223] Spence, JR, Mayhew, CN, Rankin, SA, Kuhar, MF, Valiance, JE, Tolle, K., Hoskins, EE, Kalinichenko, VV, Wells, Si., Zorn, AM, et al. (2011). Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470, 105-109.

[0224] Thanasupawat, T., Hammje, K., Adham, I., Ghia, JE, Del Bigio, MR, Krcek, J., Hoang-Vu, C., Klonisch, T., and Hombach-Klonisch, S. (2013). INSL5 is a novel marker for human enteroendocrine cells of the large intestine and neuroendocrine tumours. Oncol Rep 29, 149-154.

[0225] Tiso, N., Filippi, A., Pauls, S., Bortolussi, M. and Argenton, F. (2002). BMP signalling regulates anteroposteriorendoderm patterning in zebrafish. Mechanisms of Development 118, 29-37.

[0226] Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., and Pachter, L. (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7, 562-578.

[0227] Uppal, K., Tubbs, R.S., Matusz, P., Shaffer, K., and Loukas, M. (2011). Meckel's diverticulum: a review. Clin Anat 24, 416-422.

[0228] van Dop, WA, Uhmann, A., Wijgerde, M., Sleddens-Linkels, E., Heijmans, J., Offerhaus, GJ, Weerman, MAV, Boeckxstaens, GE, Hommes, DW, Hardwick, JC, et al. (2009). Depletion of the Colonic Epithelial Precursor Cell Compartment Upon Conditional Activation of the Hedgehog Pathway. Gastroenterology 136, 2195-2203.

[0229] van Klinken, BJ, Dekker, J., van Gool, SA, van Marie, J., Buller, HA and Einerhand, AW (1998). MUCSB is the prominent mucin in human gallbladder and is also expressed in a subset of colonic goblet cells. The American journal of physiology 274, G871-878.

[0230] Walker, EM, Thompson, CA and Battle, MA (2014). GATA4 and GATA6 regulate intestinal epithelial cytodifferentiation during development. Developmental Biology 392, 283-294.

[0231] Walton, KD, Kolterud, A., Czerwinski, MJ, Bell, MJ, Prakash, A., Kushwaha, J., Grosse, AS, Schnell, S., and Gumucio, DL (2012). Hedgehog-responsive mesenchymal clusters direct patterning and emergence of intestinal villi. Proc Natl Acad Sci USA 109, 15817-15822.

[0232] Walton, KD, Kolterud, A., Grosse, AS, Hu, CB, Czerwinski, M., Richards, N. and Gumucio, DL (2009). Epithelial Hedgehog signals direct mesenchymal villus patterning through BMP. Developmental Biology 331, 489-489.

[0233] Walton, KD, Whidden, M., Kolterud, A., Shoffner, SK, Czerwinski, MJ, Kushwaha, J., Parmar, N., Chandhrasekhar, D., Freddo, AM, Schnell, S., et al. (2016). Villification in the mouse: Bmp signals control intestinal villus patterning. Development 143, 427-436.

[0234] Wang, X., Yamamoto, Y., Wilson, LH, Zhang, T., Howitt, BE, Farrow, MA, Kern, F., Ning, G., Hong, Y., Khor, CC, et al. (2015). Cloning and variation of ground state intestinal stem cells. Nature 522, 173-178.

[0235] Watson, CL, Mahe, MM, Munera, J., Howell, JC, Sundaram, N., Poling, HM, Schweitzer, Jl, Valiance, JE, Mayhew, CN, Sun, Y. et al. (2014). An in vivo model of human small intestine using pluripotent stem cells. Nat Med 20, 1310-1314.

[0236] Wehkamp, ​​J., Chu, H., Shen, B., Feathers, RW, Kays, RJ, Lee, SK and Bevins, CL (2006). Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Left 580, 5344-5350.

[0237] Whissell, G., Montagni, E., Martinelli, P., Hernando-Momblona, ​​X., Sevillano, M., Jung, P., Cortina, C., Caton, A., Abuli, A., Castells, A., et al. (2014). The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. Nat Cell Biol 16, 695-707.

[0238] Wills, A., Dickinson, K., Khokha, M., and Baker, JC (2008). Bmp signaling is necessary and sufficient for ventrolateral endoderm specification in Xenopus. Developmental Dynamics: An Official Publication of the American Association of Anatomists 237, 2177-2186.

[0239] Xue, X., Ramakrishnan, S., Anderson, E., Taylor, M., Zimmermann, EM, Spence, JR, Huang, S., Greenson, JK, and Shah, YM (2013). Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology 145, 831-841.

[0240] Yahagi, N., Kosaki, R., Ito, T., Mitsuhashi, T., Shimada, H., Tomita, M., Takahashi, T. and Kosaki, K. (2004). Position-specific expression of Hox genes along the gastrointestinal tract. Congenit Anom (Tokyo) 44, 18-26.

[0241] Zbuk, KM and Eng, C. (2007). Hamartomatous polyposis syndromes. Nat Clin Pract Gastr 4, 492-502.

[0242] Zorn, AM and Wells, JM (2009). Vertebrate endoderm development and organ formation. Annu Rev Cell Dev Biol 25, 221-251.

[0243] Unless otherwise indicated, all percentages and ratios are calculated by weight. Unless otherwise indicated, all percentages and ratios are calculated based on the total composition.

[0244] It should be understood that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such wider numerical range, as if such narrower numerical ranges were expressly written herein.

[0245] The dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise specified, each such dimension is intended to represent the recited value and a functionally equivalent range around the recited value. For example, a dimension disclosed as "20 mm" is intended to mean "about 20 mm".

[0246] Unless expressly excluded or otherwise limited, each document cited herein, including any cross-referenced or related patent or application, is incorporated herein by reference in its entirety. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it teaches, suggests, or discloses any such invention, either alone or in any combination with any other reference. In addition, if any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall prevail.

[0247] Although specific embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various other changes and modifications may be made without departing from the spirit and scope of the present invention. Therefore, it is intended that all such changes and modifications within the scope of the present invention are covered in the appended claims.

Claims

1. A method for inducing the formation of human colon organoids, comprising the following steps: a. contacting the definitive endoderm (DE) with an FGF signaling pathway activator and a WNT signaling pathway activator (e.g., a CHIRON / GSK2 inhibitor) for a period of time sufficient for the DE to form mid-hindgut spheroids; b. contacting the mid-hindgut spheroids of step (a) with a BMP activator and an EGF signaling pathway activator for a period of time sufficient to form the human colon organoids, wherein the human colon organoids express SATB2.

2. The method of claim 1, wherein the DE is derived from a precursor cell selected from the group consisting of embryonic stem cells, embryonic germ cells, induced pluripotent stem cells, mesoderm cells, definitive endoderm cells, posterior endoderm cells, hindgut cells, or a combination thereof.

3. The method of claim 1 or 2, wherein the FGF signaling pathway activator is selected from a small molecule FGF signaling pathway activator, a protein-based FGF signaling pathway activator, FGF1, FGF2, FGF3, FGF4, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, FGF23 or a combination thereof.

4. The method according to any of the preceding claims, wherein the WNT signaling pathway activator is selected from a protein Wnt signaling pathway activator, a small molecule Wnt signaling pathway activator, preferably lithium chloride; 2-amino-4,6-disubstituted pyrimidine (hetero)aryl pyrimidine; IQ1; QS11; NSC668036; DCA β-catenin; 2-amino-4-[3,4-(methylenedioxy)-benzyl-amino]-6-(3-methoxyphenyl)pyrimidine, Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, Wnt16, a GSK3 inhibitor, preferably CHIRON, or a combination thereof.

5. The method according to any one of the preceding claims, wherein the BMP activator is selected from the group consisting of BMP2, BMP4, BMP7, BMP9, small molecules that activate the BMP pathway, proteins that activate the BMP pathway, Noggin, Dorsomorphin, LDN189, DMH-1, ventromophin, and combinations thereof.

6. The method of any one of the preceding claims, wherein the period of time sufficient for the DE to form mid-hindgut spheroids is determined by the expression of CDX2 by the mid-hindgut spheroids of step (a).

7. The method of any one of the preceding claims, wherein the period of time sufficient for the mid-hindgut spheroids to form the human colon organoids is via expression of SATB2 and CDX2 by cells of the human colon organoids.

8. The method of any one of the preceding claims, wherein the HCO is characterized by the presence of colonic enteroendocrine cells (EEC).

9. The method of any of the preceding claims, wherein the HCO is characterized by the presence of crypts and is substantially free of villi.

10. The method of any preceding claim, wherein the HCO comprises colon-specific goblet cells.

11. The method of any one of the preceding claims, wherein the HCO is substantially free of Paneth cells.

12. The method of any one of the preceding claims, wherein the HCO secretes the colon-specific hormone INSL5.

13. HCO obtained according to the process of any one of claims 1 to 7.

14. A method of forming colon tissue, comprising implanting the HCO according to any one of claims 1 to 7 under the kidney capsule of a mammal, preferably a rodent, preferably an immunocompromised rodent, preferably an immunocompromised mouse.

15. A method of determining the efficacy and / or toxicity of a potential therapeutic agent for a disease selected from colitis, colon cancer, polyposis syndrome and / or irritable bowel syndrome, comprising contacting the potential therapeutic agent with a HCO according to any one of claims 1 to 12 for a period of time sufficient to determine the efficacy and / or toxicity of the potential therapeutic agent.

16. An immunocompromised rodent comprising the HCO according to any one of the preceding claims.

17. An intestinal colonoid derived from the HCO according to any one of the preceding claims.

18. The intestinal organoid of claim 17, wherein the intestinal organoid lacks one or more of immune function, innervation, blood vessels, villi, and Paneth cells.